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Abstract: We review various existing models of hepatitis C (HCV) infection and show that there are
inconsistencies between the models and known behaviour of the infection. A new model for HCV
infection is proposed, based on various dynamical processes that occur during the infection that are
described in the literature. This new model is analysed and three steady state branches of solutions
are found when there is no stem cell generation of hepatocytes. Unusually, the branch of infected
solutions that connects the uninfected branch and the pure infection branch can be found analytically
and always includes a limit point. When the action of stem cells is included, the bifurcation between
the pure infection and infected branches unfolds, leaving a single branch of infected solutions. It
is shown that this model can generate various viral load profiles that have been described in the
literature which is confirmed by fitting the model to four viral load datasets. Suggestions for possible
changes in treatment are made based on the model.
1. Introduction1
Viral diseases are major causes of human morbidity and mortality worldwide. Hepatitis C virus2
(HCV) infection is one of the major contributors in this regard. The WHO recently published a Global3
Hepatitis Report [10] which provides global estimates regarding various aspects of HCV infection.4
They report that in 2015:5
• Globally, an estimated 71 million people were living with chronic HCV infection;6
• An estimated 1.75 million new HCV infections occurred worldwide, while 399,000 died from7
end-stage HCV infection and 843,000 were cured;8
• 20% of HCV-infected persons (14 million) have been diagnosed and, of these, 7.4% (1.1 million)9
had started treatment;10
• HCV infection affects all regions with the highest reported prevalence in the Eastern Mediterranean11
and European Regions.12
The report also noted that incidence of HCV infection in the USA doubled between 2010 and 2014.13
Thus, HCV infection is still an issue of major importance for global public health.14
In May 2016, the World Health Assembly adopted the Global Health Sector Strategy which15
committed to a 65% reduction in mortality and a 90% reduction in incidence by 2030 [10]. Clearly,16
given the above statistics, there is much work to do in order to achieve these targets. A good17
understanding of the disease mechanism is vital in designing new drugs for treatment of the infection.18
This understanding is somewhat hampered by the fact that data can only be easily collected for the19
viral load, and so other quantities, such as the concentration of healthy and infected hepatocytes,20
cannot be determined from patient data.21
Mathematical modelling allows the inclusion of all the relevant variables and can help to give22
insight into disease progression and the effect of treatment. Many different mathematical models have23
been proposed for HCV infection (as well as for many other viral infections) and we add our own24
new model to this collection. One of the early HCV models by Neumann et al. [18] was adapted from25
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similar models of HBV and HIV infections. Other models have since been proposed, many of which are26
variations on this original model. However, these models are not consistent with some of the known27
facts about HCV infection. Thus, we review some of the information about HCV infection that is28
available in the biological literature and propose a new model that is consistent with this information.29
Having derived a new model, we then analyse the steady state solutions and, unusually for a30
nonlinear model, we are able to give an analytic solution for the infected steady state solutions. There31
are many different viral load profiles described in the literature, and we describe how each of these32
can be achieved with our model. We also make some suggestions for changes in treatment of HCV33
infection, based on our model predictions.34
2. A Review of Existing Models of HCV Infection35
A number of different mathematical models have been proposed for modelling the dynamics of36
HCV infection. We first review some of the existing models, before proposing one of our own.37
2.1. The Neumann Model38
Neumann at al. [18] adapted models of HIV and HBV infections to HCV and derived the equations39
T˙ = s− dT − (1− η)βVT (1)
I˙ = (1− η)βVT − δI (2)
V˙ = (1− e)pI − cV (3)
where T is the concentration of healthy hepatocytes, I is the concentration of infected hepatocytes, V is40
the concentration of virions and the dot represents the derivative with respect to time. The treatment41
parameters η and e correspond to a reduction in the rate of production of infected cells and42
virions respectively.43
These equations have an uninfected steady state
Tu =
s
d
, Iu = Vu = 0 (4)
which exists for all η and e, together with an infected steady state44
Ti =
δc
βp(1− η)(1− e)
Ii =
s
δ
− cd
βp(1− η)(1− e)
Vi =
sp(1− e)
δc
− d
β(1− η)
The two branches intersect at a bifurcation point at
(1− η)(1− e) = δcd
βsp
(5)
2.2. The First Dahari Model45
Dahari et al. [4] analysed the Neumann model and showed that the solutions could exhibit46
biphasic decline of the viral load under treatment, with an initial rapid decline followed by a slower47
decline, but that it could not show triphasic behaviour of the viral load, where a plateau exists between48
the rapid and slow declines. They therefore developed an extended model by adapting the Neumann49
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model, including extra terms for the replication of the healthy and infected hepatocytes. Their model50
equations are given by51
T˙ = s− dT + rT
(
1− T + I
Tmax
)
− (1− η)βVT (6)
I˙ = (1− η)βVT + rI
(
1− T + I
Tmax
)
− δI (7)
V˙ = (1− e)pI − cV (8)
These equations also have an uninfected steady state with Iu = Vu = 0 and Tu is found as the
positive solution of the quadratic equation
rT2 − Tmax(r− d)T − sTmax = 0 (9)
We note that this quadratic equation has one positive and one negative solution, and clearly the
positive solution is the one of interest. Substituting T = Tmax + δT into (9) gives the quadratic equation
rδT2 + Tmax(r+ d)δT + Tmax(Tmaxd− s) = 0 (10)
The number of positive or negative solutions of this equation depends on the sign of Tmaxd− s.
If this term is positive, then both the solutions are negative and so the two solutions of (9) will both
lie below Tmax. However, if this term is negative, then (10) will have one positive and one negative
solution. Clearly the negative solution will correspond to the negative solution of (9) and so the
positive solution must correspond to T > Tmax. Now Tmax is supposed to be the maximum value for
the healthy hepatocytes, and so we maintain this upper bound provided that the condition
Tmax >
s
d
is satisfied.52
The Equations (6)–(8) also have an infected steady state given by53
Ii =
c(Tmax(s+ (r− d)Ti)− rT2i )
Ti(rc+ (1− η)(1− e)pβTmax)
Vi =
ep(Tmax(s+ (r− d)Ti)− rT2i )
Ti(rc+ (1− η)(1− e)pβTmax)
where Ti is the positive solution of the quadratic equation
(1− η)2(1− e)2β2p2TmaxT2 + c((1− η)(1− e)βpTmax(r− δ)− cr(δ− d))T − rsc2 = 0 (11)
which also has one positive and one negative solution. Clearly the positive solution is the only solution
of interest. The two branches again intersect at a bifurcation point which occurs at
(1− η)(1− e) = c(rTi − Tmax(r− δ))
pβTmaxTi
Note however that Ti also depends on η and e.54
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2.3. The Second Dahari Model55
If ribavirin is included as part of the treatment, then it causes some of the virions to be56
non-infectious. Dahari et al. [5] modelled this by separating the virions into two groups, namely57
infectious (VI) and non-infectious (VNI). The equations that they derived are given by58
T˙ = s− dT + rTT
(
1− T + I
Tmax
)
− (1− η)βVIT (12)
I˙ = (1− η)βVIT + rI I
(
1− T + I
Tmax
)
− δI (13)
V˙I = (1− ρ(t))(1− e)pI − cVI (14)
V˙NI = ρ(t)(1− e)pI − cVNI (15)
where ρ(t) is the fraction of virions that are rendered noninfectious due to the effect of ribavirin.59
Snoeck et al. [24] simplified these equations by taking rT = rI and by making ρ a constant rather than60
a time dependent function. We now review the solutions of these simplified equations.61
The first three Equations (12)–(14) involve only the three variables T, I and VI and so these
equations decouple from the fourth. These equations are essentially the same as Equations (6)–(8),
except that V is replaced by VI and p is replaced by (1 − ρ)p. Thus, the uninfected steady state
is the same as for the first Dahari equations, together with VNI = 0. The infected steady state is
readily obtained from the first Dahari steady state by replacing p with (1− ρ)p in the above equations
together with
VNI,i =
ρ(1− e)p
c
Ii
Similarly, the bifurcation point at which the two branches intersect occurs at
(1− η)(1− e)(1− ρ) = c(rTi − Tmax(r− δ))
pβTmaxTi
where Ti is the positive solution of (11).62
2.4. Other Models63
There are also a number of variants of the above models in the literature. Herrman et al. [14]
used Equations (2) and (3) from the Neumann model, but used a different equation for the healthy
hepatocytes given by
T˙ = γ(T(0) + I(0)− T − I)
We note that this equation does not include the term −βVT associated with the virus infecting64
the healthy cells. Also the rate of production of the healthy cells depends on the difference between the65
maximum value T(0) + I(0) and the total hepatocyte population T+ I. After an initial time period,66
they change δ in (2) to Mδ for some M > 1 to represent an inflated loss of infected cells after an initial67
delay.68
Song and Neumann [25] also use Equations (2) and (3) from the Neumann model and supplement
this with the equation for T given by
T˙ = s− dT + aT(1− T/Tmax)− βVT
In this case, the proliferation is modelled by a logistic function, but the reason for this choice is not69
given. They also adapt this model by including a saturation term for the generation of infected cells70
where they replace the βVT term by βVT/(1+ αV).71
An earlier model by Dahari et al. [3] is very similar to the first Dahari model described above, but72
with a time dependent component for the death rate of infected cells and a time dependent treatment73
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parameter e(t) and an extra equation for the dynamics of ALT. There is also a term q(t)I which is74
added to the T equation and subtracted from the I equation which represents noncytolytic clearance75
of the virus from infected cells. These extra terms were dropped in the later models by Dahari et al.76
This early model was analysed in more detail by Reluga et al. [20] but with q constant, which is then77
described as a spontaneous cure term.78
3. A New Model of HCV Infection79
Clearly there are many mathematical models of HCV infection which are generally similar in80
nature but with a variety of different terms occurring in the equations which represent different81
biological processes. We now add to this collection of models by developing our own model. We82
consider the available literature concerning the various dynamical processes that occur during HCV83
infection and treatment and include those that we consider to be the most important into the model.84
3.1. Cell Regeneration85
The liver is unique among the organs of the body in that it can regenerate itself if part of the liver
mass is removed [26]. We therefore begin by considering the dynamics of healthy hepatocytes in an
uninfected liver. All of the models described in Section 2 include the terms
T˙ = s− dT (16)
The standard interpretation of this equation is that new hepatocytes are formed at a constant
rate s and that a certain fraction d of them die. However, hepatocyte turnover is low in a normal
liver with more than 99% in the quiescent phase of the cell cycle. But if part of the liver is removed
in a partial hepatectomy, then the liver mass is replaced within 7 days by replication of the mature
hepatocytes [17]. Thus, if the concentration T is measured relative to the original volume of the liver,
then we model this cell division process by
T˙ = r(Tmax − T)
so that the concentration is reduced when part of the liver is removed and the division process stops
completely when T reaches Tmax. Including the term for cell death gives the equation
T˙ = r(Tmax − T)− dT = rTmax − (r+ d)T (17)
where d must be small to ensure slow turnover in a healthy liver. This equation has steady state86
Ts = rTmax/(r+ d). We note that this equation is essentially the same as (16) with s = rTmax and87
d replaced by r+ d. Thus, this equation seems reasonable, but the interpretation of the parameters88
requires care.89
It has been found that the liver regenerates itself after surgery with approximately exponential
convergence to a steady state [19] as can be seen in Figure 1 (although the regeneration in the first
7 days seems to occur more rapidly than predicted by the fitted curve). The solution of Equation
(17) also consists of exponential convergence to the steady state. However, care must be exercised in
linking these as the plots in Figure 1 are for liver volume, whereas T is a concentration of hepatocytes.
However, T/Ts is the ratio of the reduced number of hepatocytes to the number of hepatocytes in
the liver before surgery, which is the same as the ratio of liver volume after surgery to volume before
surgery. Dividing (17) by Ts gives
T˙
Ts
=
rTmax
Ts
− (r+ d) T
Ts
= (r+ d)
(
1− T
Ts
)
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(a) Female liver regeneration.
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(b) Male liver regeneration.
Figure 1. Data for female and male liver regeneration from [19] fitted with a curve of the form
y = a− be−ct, which is the form of the solution of (17).
The solution of this equation is
T
Ts
= 1− Ae−(r+d)t
where the constant A is determined from the initial condition. This solution can be multiplied by 10090
to give a percentage figure, which does not affect the exponential term. Of course, the data shown in91
Figure 1 indicates that the liver does completely regain its previous volume and so we cannot match92
this solution precisely to the data. However, we assume that the exponential rate of convergence is the93
same which implies that the coefficient of the exponential of the percentage of original liver volume is94
r+ d. This is consistent with the solution of Equation (17).95
Fitting a function of the form y = a− be−ct to the data shown in Figure 1 gives the curves shown.96
The corresponding parameter values are a = 79.8889, b = 23.8424, c = 0.0153121 for the female data97
and a = 86.0996, b = 29.1096, c = 0.0111078 for the male data. Thus, we have r+ d = 1.53× 10−2 for98
the female data and the slightly lower value of r+ d = 1.11× 10−2 for the male data.99
For an HCV infected liver, it is assumed in Dahari et al. [3] that the regeneration of the liver occurs
through “blind homeostatis” in which the infected cells regenerate in the same way as the healthy
cells. We make this assumption here, but will revisit this issue later. Thus, if we define H = T + I, to
be the total concentration of hepatocytes, then the equation for H should be the same as our previous
equation (17) but with T replaced by H, which is therefore given by
H˙ = rTmax − (r+ d)H (18)
We note that considering only the regeneration terms in the first Dahari model [3] and the variant of100
the second Dahari model by Snoeck et al. [24], the regeneration terms in the equations for T and I are101
T˙ = rT
(
1− T + I
Tmax
)
I˙ = rI
(
1− T + I
Tmax
)
Adding these equations gives
H˙ = rH
(
1− H
Tmax
)
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which is a logistic equation for the growth of hepatocytes. The dynamics of the logistic equation ends102
with exponential convergence to a steady state, but has slower growth at an earlier stage, particularly103
for initial conditions that are not close to the stable steady state. This does not agree with the above104
results that show exponential convergence to the steady state but with more rapid initial growth.105
Thus, we allocate the growth of H, given by r(Tmax − H), to the two pools T and I in relative106
proportion to the size of the pools, noting that the size of the pools is not constant over time. We107
therefore have the equations108
T˙ = r
T
T + I
(Tmax − (T + I))
I˙ = r
I
T + I
(Tmax − (T + I))
Adding these equations gives the regeneration term in (18) as we required.109
It is generally assumed that the death rates of the healthy and infected cells are different, as the110
immune system tries to get rid of the infected hepatocytes resulting in a higher death rate. Thus,111
adding in the death terms gives the equations112
T˙ = r
T
T + I
(Tmax − (T + I))− dT
=
rTmaxT
T + I
− (r+ d)T
I˙ = r
I
T + I
(Tmax − (T + I))− δI
=
rTmax I
T + I
− (r+ δ)I
Setting δ = d and adding these equations then gives (18). However, since the death rate for infected113
cells is higher than for healthy cells, we assume that δ > d.114
We made the assumption above that the healthy and infected cells regenerate in the same way115
which implies that the total number of hepatocytes H is not changed by progression of the infection116
(except for the increased death rate of the infected cells). However, it is known that “the vast majority117
of liver diseases are characterized by various levels of damage, loss, and impaired regeneration of118
mature hepatocytes” [7]. Hepatocyte loss due to disease has been classed as mild (<30%), moderate119
(30–50%) or severe (>50%) [16] and so it is clear that infection does result in quite significant loss of120
hepatocytes. As noted above, the infection also impairs the regeneration of mature hepatocytes, and so121
this should be included in the model. We do this by assuming that the regeneration rates of healthy122
and infected hepatocytes are different (as is done in DebRoy et al. [8]) and so our equations now123
become124
T˙ = rT
T
T + I
(Tmax − (T + I))− dT
=
rTTmaxT
T + I
− (rT + d)T
I˙ = rI
I
T + I
(Tmax − (T + I))− δI
=
rITmax I
T + I
− (rI + δ)I
where the two constants rT and rI determine the rate of proliferation of the healthy and infected125
hepatocytes respectively. DebRoy et al. [8] assume that rI > rT so that the proliferation of infected126
cells is greater than that for uninfected cells. It has been noted that chronic HCV infection results in127
increased expression of proliferation markers [17], which suggests an increase in the proliferation rate128
due to infection. However, it has also been found that progression to the S phase of the cell cycle is129
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blocked, so that there is overall a reduction in the number of cells that complete the cell cycle. This is130
related to the virus in the cells since “cell cycle progression (is) blocked by individual viral proteins”131
[17]. We therefore assume that rI < rT so that proliferation of infected cells is reduced. This is also the132
assumption made by Dahari et al. [5]. A combination of healthy cells becoming infected, a lower rate133
of regeneration for infected cells and a higher rate of cell death for infected cells is likely to result in a134
large decrease in the total number of hepatocytes as the infection progresses, as has been observed.135
3.2. Stem Cells136
Thus far, we have considered hepatocyte production only as a result of cell division. However,137
liver stem cells can also generate hepatocytes and so there are two mechanisms for hepatocyte138
production [7,26,28]. In a healthy liver which has undergone a partial hepatectomy (where part139
of the liver has been removed), the healthy hepatocytes self-replicate to restore liver mass and the140
contribution of liver stem cells to regeneration “seems to be minimal if any” [26]. However, if there is141
liver injury which affects this mechanism of regeneration, such as due to chronic viral hepatitis, then142
the stem cells become more active as an alternative mechanism of hepatocyte production [7,26,28].143
Moreover, “a 50% loss of hepatocytes, together with a significant decrease in proliferation of the144
remaining mature hepatocytes, is required for an extensive activation of hepatic progenitors” [7]. Thus,145
it seems that the activation of stem cells is proportional to the degree of infection, with no effect in a146
healthy liver and an extensive effect in a severely infected liver. We model this by adding a term sI to147
the equation for T, giving the model equations which include these two mechanisms of hepatocyte148
production together with cell death as149
T˙ = sI +
rTTmaxT
T + I
− (rT + d)T
I˙ =
rITmax I
T + I
− (rI + δ)I
3.3. Infection150
Infected hepatocytes are formed when virions enter healthy hepatocytes. The principle of mass151
action implies that the infection rate is proportional to the product of the concentrations of virions and152
healthy cells. Adding the infection terms into our earlier equations now gives153
T˙ = sI +
rTmaxT
T + I
− (r+ d)T − βVT
I˙ =
rTmax I
T + I
− (r+ δ)I + βVT
V˙ = −cV − βVT
where we have also included an elimination term in the V equation. We note that all of the models154
discussed above omit the infection term in the V equation. In Dahari et al. [5] they point out that155
if T is assumed to be constant, then −cV − βVT = −(c+ βT)V = −c˜V and so the infection term156
can be considered to be included in the elimination term −cV. However, as the models all include157
a differential equation for T, it is clearly not constant. Moreover, in the case of severe infection, the158
concentration of healthy hepatocytes may be very low, and so the assumption that T is approximately159
constant is not valid. Thus, the infection term should also be included in the V equation. We note that160
models for HIV infection are very similar to these models, and in this case, the infection term is also161
included in all three equations [1].162
3.4. The Revised Model163
Finally, assuming that infected cells produce virions at a constant rate p, we add an extra term into164
the V equation. Treatment with interferon alpha is assumed to both reduce the rate of new infection165
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(η) and reduce the rate of production of virions (e). Adding in these treatment parameters, we obtain166
our revised model equations167
T˙ = sI +
rTTmaxT
T + I
− (rT + d)T − (1− η)βVT (19)
I˙ =
rITmax I
T + I
− (rI + δ)I + (1− η)βVT (20)
V˙ = (1− e)pI − cV − (1− η)βVT (21)
If the effect of ribavirin is included, which causes some of the virions to be non-infectious, then the168
model becomes169
T˙ = sI +
rTTmaxT
T + I
− (rT + d)T − (1− η)βVIT (22)
I˙ =
rITmax I
T + I
− (rI + δ)I + (1− η)βVIT (23)
V˙I = (1− ρ)(1− e)pI − cVI − (1− η)βVIT (24)
V˙NI = ρ(1− e)pI − cVNI (25)
Again, the last equation decouples from the other three, and so the dynamics of the system is170
determined by Equations (22)–(24), which are essentially the same as Equations (19)–(21) with VI171
replaced by V. Thus, we only consider Equations (19)–(21) in detail.172
3.5. Spontaneous Clearance173
It has been reported that “about 15–30% of asymptomatic patients and more than 50% of174
symptomatic patients with acute hepatitis C spontaneously clear the virus during the early phase of175
infection” [3]. A more recent estimate is that “15–45% of [HCV] infected persons spontaneously clear176
the virus within 6 months of infection without any treatment” [13]. For infected patients who are cured177
by treatment, it is also likely that the treatment does not completely eliminate all infected hepatocytes178
and virions, but that the body is able to clear a small remnant once treatment has stopped. Both these179
situations can occur in the equations by ensuring that the uninfected steady state is stable when there180
is no treatment (e = η = 0) for initial conditions sufficiently close to the steady state. However, the181
Neumann model and the two Dahari models described above do not allow for this possibility as the182
model equations with the treatment parameters e and η set to zero all have the uninfected steady state183
as unstable.184
The model described in Dahari et al. [3] includes terms (qI) for noncytolytic clearance of the virus185
from infected cells. These terms are described in Reluga et al. [20] as being associated with spontaneous186
cure. In [20], a quasi-steady state approximation is used to reduce the three equations to two. The187
eigenvalues of the Jacobian evaluated at the uninfected steady state are λ1 < 0 and λ2(q) = λ2(0)− q,188
where λ2(0) is the difference of positive terms and so could be positive or negative. So clearly189
the addition of the parameter q ensures that a larger region of the parameter space corresponds to190
spontaneous cure since it moves the eigenvalue λ2 to the left on the real line. However, this term was191
dropped in later models used by this group [4,5].192
Spontaneous clearance and clearance of infection after cessation of treatment can both be193
realised in a model by ensuring that the uninfected steady state is stable with no treatment but194
with another nearby steady state also existing which has one unstable and two stable eigenvalues.195
The two-dimensional stable manifold would then act as a surface that separates out trajectories that196
converge to the uninfected steady state or move away from this region to a stable infected steady state.197
Chronic infection would then occur if either the initial conditions at the start of infection lie above this198
two-dimensional stable manifold, or if, for particular parameter values, the uninfected steady state199
had become unstable, in which case a complete cure with treatment would also be impossible.200
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Figure 2. The bifurcation from the uninfected steady state. The bifurcation point occurs for (a) e < 0,
(b) e = 0, (c) e > 0. Stable steady states are indicated by solid lines and unstable steady states by
dashed lines.
All the models have an uninfected steady state with I = V = 0 and T > 0. One way in which the201
scenario just described could occur is if the bifurcation from the uninfected steady state to an infected202
steady state occurs close to e = 0. If the bifurcation point occurs for e < 0, at an unphysical parameter203
value, with the bifurcating branch occurring to the right of the bifurcation point then there would204
be two steady state solutions at e = 0 with the uninfected steady state being stable and the infected205
steady state being unstable (see Figure 2(a)). This situation allows for spontaneous cure or chronic206
infection, depending on the initial conditions, and for complete cure for a patient once the treatment207
has reduced the infected hepatocytes and virus levels to a sufficiently low level. However, only a small208
change in parameter values could move this bifurcation point so that it occurs for a positive value of e209
(see Figure 2(c)) which makes the uninfected steady state without treatment to be unstable. In this case,210
spontaneous clearance of the infection is not possible and there will always be relapse of the infection211
on cessation of treatment, as is observed in some cases [24]. Clearly only a small change in parameters212
is required to switch between these cases which could be due to the variability between patients and213
would also explain the variability in outcomes for different patients. Various different scenarios will be214
considered in more detail in Section 8.215
3.6. Non-Dimensionalisation216
Before considering the properties of our new model in detail, we non-dimensionalise it in order to
reduce the number of parameters. We non-dimensionalise Equations (19)–(21) by rescaling the variables
by the uninfected steady state value of T which is Tu = rTTmax/(rT + d). (Note that Tu < Tmax.) We
therefore define the new non-dimensional variables
x =
(rT + d)T
rTTmax
, y =
(rT + d)I
rTTmax
, z =
(rT + d)V
rTTmax
(26)
together with a new non-dimensional time variable
τ = (rT + d)t
The Equations (19)–(21) involve two treatment parameters e and η. IFN therapy is assumed
to partially block viral production (e) and to reduce the rate of production of infected cells (η) [22],
which implies that both the treatment parameters are non-zero. For a bifurcation analysis, it is more
convenient to have a single bifurcation parameter, and so we also make the assumption that
η = αe (27)
for some α > 0. It has been shown that the major effect of interferon is to block production or release
of virions from an infected cell [18], and this implies that
α < 1 (28)
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The equations in terms of all these new variables are then given by217
x′ = Sy+ x
x+ y
− x− (1− αe)Bxz (29)
y′ = 1
1+ R
(
y
x+ y
− y
)
− Dy+ (1− αe)Bxz (30)
z′ = (1− e)Py− Cz− (1− αe)Bxz (31)
where the prime denotes derivatives with respect to τ and the non-dimensional parameters are given by
S =
s
rT + d
, B =
βrTTmax
(rT + d)2
, R =
rT
rI
− 1, D = rTδ− rId
rT(rT + d)
, P =
p
rT + d
, C =
c
rT + d
(32)
We note that our previous assumptions that rI < rT and d < δ imply that D > 0. We also explain218
our choice of the parameter R. The coefficient multiplying the first term in (30) is rI/rT and this satisfies219
0 < rI/rT < 1. We generally define parameters so that they are positive, but in this case we have two220
conditions to satisfy. However, we note that these two conditions are equivalent to the single condition221
rT/rI > 1, since it is implicitly assumed that the ratio is finite. Thus, we define R = rT/rI − 1 and note222
that R → ∞ as rI/rT → 0 and R = 0 when rI/rT = 1. Thus, the single condition R > 0 ensures that223
both conditions on the ratio rI/rT are satisfied. We note therefore that all of these non-dimensional224
parameters must be positive.225
We also require that e ∈ [0, 1) which ensures that the treatment factor 1− e is positive, which then226
also implies that 1− αe is positive using (28).227
4. Validation of the New HCV Model228
In order to validate our new HCV model, we need to check some fundamental mathematical229
and biological properties of the model. From a mathematical perspective, we need to ensure that230
the equations are well-posed (a solution exists, is unique and depends continuously on the initial231
conditions). From a biological perspective, we must show that the solutions are non-negative for all232
time and are bounded.233
All of our variables must be non-negative as they are related to physical quantities and so we
first show that the non-dimensional Equations (29)–(31) have an invariant region within the octant
x, y, z ≥ 0. Using polar coordinates defined by x = r cos θ, y = r sin θ, we see that
x
x+ y
=
cos θ
cos θ + sin θ
,
y
x+ y
=
sin θ
cos θ + sin θ
and so the quotients that occur in Equations (29) and (30) are well defined in the limit r → 0 along rays234
with fixed θ for 0 ≤ θ ≤ pi/2. However, this also implies that the vector field is not uniquely defined235
along the z axis, and so we exclude a neighbourhood of this axis. In a modelling context, the z axis236
(x = y = 0) corresponds to there being no healthy or infected hepatocytes, which is unrealistic.237
Theorem 1.238
We define the octant O = {(x, y, z) ∈ R3 : x, y, z ≥ 0} and a cylinder around the z axis C = {(x, y, z) ∈239
R3 : x2 + y2 < r20, z ≥ 0}. The regionR = O\C is invariant under the flow of Equations (29)–(31) for240
sufficiently small r0 > 0. Moreover, the line y = z = 0, x ≥ r0 is an invariant line, corresponding to241
the dynamics of a healthy liver, on which x converges exponentially to the steady state x = 1 for all242
x(0) ≥ r0.243
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Proof.
We first consider the line given by y = z = 0, x ≥ r0. On this line we have y′ = z′ = 0 and so it is
invariant for all time and the flow is given by
x′ = 1− x
The solution of this equation consists of exponential convergence to the steady state x = 1 for all244
x(0) ≥ r0.245
The region R is bounded by the planes P1 (x = 0, y ≥ r0, z ≥ 0), P2 (x ≥ r0, y = 0, z ≥ 0), and246
P3 (x2 + y2 ≥ r20, z = 0) together with the surface S = {(x, y, z) ∈ R3 : x2 + y2 = r20} ∩ O. We will247
show that the vector field given by Equations (29)–(31) on these surfaces is directed inside the region248
R except for the invariant line.249
Taking the inner product of the vector field with the inward pointing normal on the plane P1 we
see from (29) that
x′|P1 = Sy
and so x′|P1 > 0 on this plane since y ≥ r0 > 0. Thus, the vector field is directed inside R on this250
plane.251
Similarly, from (30) we have
y′|P2 = (1− αe)Bxz
and so y′|P2 > 0 for z > 0 (since 1− αe > 0 using (37), (38)) and y′|P2 = 0 for z = 0, which is the252
invariant line. Thus, the vector field is directed insideR on this plane, except for the invariant line.253
From (31) we also have
z′|P3 = (1− e)Py
and so z′|P3 is positive everywhere except on the invariant line, since 1− e > 0 (using (38)).254
Finally, we consider the surface S . The normal to this surface points in the r direction when
x = r cos θ, y = r sin θ. Differentiating the equation x2 + y2 = r2 with respect to τ and using (29), (30)
gives
r′ = 1+ R cos
2 θ
(1+ R)(cos θ + sin θ)
+O(r)
Therefore r′|r=0 > 0, since θ is in the first quadrant, and this implies that r′|r=r0 > 0 for sufficiently255
small r0, 0 ≤ θ ≤ pi/2, z ≥ 0. Thus the vector field points insideR also on this surface.256
Thus, we conclude that any trajectory with (x(0), y(0), z(0)) ∈ R = O\C must satisfy257
(x(t), y(t), z(t)) ∈ R for all t > 0 and soR is invariant.258
We now show that our model equations are well-posed on the regionR.259
Theorem 2.260
The model Equations (29)–(31) are well-posed on the regionR defined in Theorem 1.261
Proof.262
The well-posed condition requires local existence and uniqueness of solutions of the model equations.263
For the system of differential equations given by u′ = f (u, t), u(t0) = u0 with u ∈ Rn, if the function f264
is continuous and satisfies a Lipschitz condition in u on a region |t− t0| ≤ α, ||u− u0|| ≤ β then it is265
well-posed [11] and there is then a unique solution on an interval |t− t0| ≤ δ for some δ ≤ α.266
For our model equations given by (29)–(31), the continuity and Lipschitz conditions are satisfied267
for any such bounded region in the positive octant if the terms x/(x+ y) in (29) and y/(x+ y) in (30)268
are excluded. Once the cylinder C in the positive octant is excluded, then these nonlinear terms also269
satisfy a Lipschitz condition on any bounded region since x+ y is bounded below by r0. Therefore our270
model equations are well-posed.271
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Figure 3. The invariant region in the positive octant bounded by the cylinder C (see Theorem 1) and
the plane (34).
It remains to show that the solutions are bounded for all time, which we can do provided that a272
condition on the parameters holds, and this will also imply global existence of solutions.273
Theorem 3.
If
min(S, (1− e)P)(1+ R)− (1+ D(1+ R)) < 0 (33)
then there is a bounded invariant region contained in the regionR (defined in Theorem 1). In this case,274
the solution of Equations (29)–(31) exists and is bounded for all t ≥ 0 for any finite initial conditions.275
We note that this Theorem gives a sufficient condition for bounded solutions. If this condition is276
not satisfied, it may still be the case that the solutions are bounded.277
Proof.
We show that the regionR defined in Theorem 1 (the positive octant with a cylinder around the z axis
removed) together with the additional restriction that
wx+ y+ (1− w)z ≤ k
is a bounded invariant region for k > 0 sufficiently large and for all w ∈ (0, 1) provided that a condition278
on the parameters is satisfied. We note that this region is not bounded for w = 0 and w = 1, which is279
why we require that w ∈ (0, 1). This region is shown in Figure 3.280
Since we have already shown that the region R is invariant, it remains to show that the vector
field is directed inside the bounded region on the plane
wx+ y+ (1− w)z = k (34)
when the condition (33) holds.281
Using the model Equations (29)–(31), we see that282
wx′ + y′ + (1− w)z′ = −wx+
(
wS− 1
1+ R
− D+ (1− w)(1− e)P
)
y− (1− w)Cz
+
wx
x+ y
+
(
1
1+ R
)(
y
x+ y
)
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and substituting for z using (34) gives283
wx′ + y′ + (1− w)z′ = (C− 1)wx+
(
wS− 1
1+ R
− D+ (1− w)(1− e)P+ C
)
y− Ck
+
wx
x+ y
+
(
1
1+ R
)(
y
x+ y
)
(35)
We first omit the nonlinear terms and so consider the function
f (x, y) = (C− 1)wx+
(
wS− 1
1+ R
− D+ (1− w)(1− e)P+ C
)
y− Ck
which is a linear function of x and y. We first show that this function is negative at the three corner284
points of the triangle where the plane (34) intersects the positive octant O, ignoring the excluded285
cylinder C at this stage. The function evaluated at these corner points is given by286
f (0, 0) = −Ck
f (0, k) =
(
wS− 1
1+ R
− D+ (1− w)(1− e)P
)
k
f (k/w, 0) = −k
If we assume that
wS− 1
1+ R
− D+ (1− w)(1− e)P < 0 (36)
then f (x, y) is negative at all three of the corner points for all k > 0. Since it is a linear function of x287
and y, this implies that it must also be negative on the boundary and the interior of the triangular288
region generated by these three points.289
We have so far ignored the two nonlinear terms in (35), which are both positive. We note that
0 ≤ x
x+ y
≤ 1 for all (x, y) ∈ R
and so
0 ≤ wx
x+ y
≤ w for all (x, y) ∈ R
Similarly,
0 ≤
(
1
1+ R
)(
y
x+ y
)
≤
(
1
1+ R
)
for all (x, y) ∈ R
Thus, these two nonlinear terms are uniformly bounded above. Now the corner points of the linear290
function f (x, y) scale with k, and so f (x, y) will scale with k for all x and y. Hence, when adding291
the bounded nonlinear terms to f (x, y), the resulting function will be negative over the whole of the292
triangular region for sufficiently large k. Hence the vector field points inside the invariant region293
over the whole of the plane (34) intersected with the positive octant provided that (36) holds and k is294
chosen sufficiently large and the bounded region (which excludes the cylinder C) is then invariant. For295
any given initial conditions, k must also be chosen sufficiently large so that the initial conditions are296
contained within the invariant region. The solution must therefore be bounded for all time.297
We next consider the condition (36) in more detail. Suppose that (1− e)P < S. Then when
w ∈ (0, 1), we have that
wS+ (1− w)(1− e)P ∈ ((1− e)P, S)
Thus, if (1− e)P− 1/(1+ R)− D < 0 (w = 0), then by the Intermediate Value Theorem, there exists a298
small w > 0 such that (36) holds also. A similar argument holds if (1− e)P > S with the condition299
S− 1/(1+ R)− D < 0. Thus, the optimum value of wS+ (1− w)(1− e)P to choose to be as small as300
Viruses 2018, xx, x 15 of 41
possible is S if S < (1− e)P or (1− e)P if S > (1− e)P, which is equivalent to min(S, (1− e)P), and301
this gives the condition (33) in the statement of the Theorem after multiplying through by (1+ R).302
It is a standard result in ode theory that if the function is continuous and satisfies a Lipschitz303
condition for all t ≥ 0 and on a given domain, then solutions either exist for all time or blow up in finite304
time [11]. On the bounded domain described above, the Equations (29)–(31) satisfy these conditions,305
using the same argument as in the proof of Theorem 2, and since we have shown that the solutions are306
bounded if (33) holds, then this implies that the solution exists for all t ≥ 0.307
5. Analysis of the New HCV Model308
We now consider the steady states and their bifurcations of the new HCV model given by309
Equations (19)–(21), together with dynamical properties of the model.310
5.1. Assumptions311
In our analysis, we make a number of assumptions on the parameters. Rather have them scattered312
through the text, we now state our main assumptions together for later reference. The key assumptions313
that we make on the parameters are as follows:314
α ∈ (0, 1) (37)
e ∈ [0, 1) (38)
(B+ C)(B− CR) > BCP(1+ R) (39)
D =
BP
B+ C
(40)
The justification for the first two of these conditions was given in Section 3.6, and we assume that315
these always hold. When we require assumptions (39) and (40), this will stated.316
Note that if (39) holds then
B > CR (41)
must also hold. Moreover, if (39) holds, then
B+ C > CP
(
B(1+ R)
B− CR
)
We note that B(1+ R) > B > B− CR and so B(1+ R)/(B− CR) > 1. It then follows that
B > C(P− 1) (42)
5.2. Steady States (S = 0)317
We consider the steady states of our revised model (29)–(31) in the special case when S = 0. In318
Section 5.4, we will show how these states are perturbed when S > 0.319
When S = 0, there is a branch of uninfected steady states given by
xu = 1, yu = zu = 0 (43)
for all e ∈ [0, 1).320
Due to the absence of the S term, there is a state of pure infection given by
xp = 0, yp =
1
1+ D(1+ R)
, zp(e) =
(1− e)P
C(1+ D(1+ R))
(44)
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since, if the only mechanism for cell regeneration is by division and there are no healthy hepatocytes321
(x = 0), then that state will persist as there are no healthy cells to divide. We note that xp and yp are322
constant, but that zp depends on e.323
There is also a branch of infected steady states given by324
xi(e) =
C(1+ D(1+ R))zi(e)− (1− e)P
f (zi(e), e)
yi(e) =
zi(e)[BCR(1− αe)zi(e)− (B(1− αe) + C)]
f (zi(e), e)
where
f (zi(e), e) = B(1− αe)[(1− e)PR− 1− D(1+ R)]zi(e)− (1− e)P (45)
and zi(e) is a solution of the quadratic equation
B2CR(1− αe)2z2 + B(1− αe)(C(R+ D(1+ R))− B(1− αe))z
+ (1+ R)[B(1− αe)(D− (1− e)P) + CD] = 0 (46)
These solutions will only be valid provided that f (zi(e), e) 6= 0 for all e ∈ [0, 1). We note that325
f (z, e) is quadratic in e and that for all z > 0326
f (z, 1) = −B(1− α)[1+ D(1+ R)]z < 0
f
(
z,
1
α
)
=
(1− α)P
α
> 0
since α < 1 (see (37)). Thus, there exists a function e˜(z) such that f (z, e˜(z)) = 0 with 1 < e˜(z) < 1/α327
for all z > 0, which is clearly outside our range of interest.328
The coefficient of e2 in f (z, e) is αBPRz which is positive for all z > 0 and this implies that the
second value of e that gives f (z, e) = 0 must occur for e < 1. In order to avoid the infected steady
state branch blowing up in our range of interest, we require that this second root occur for e < 0 and
this will be the case provided that f (z, 0) < 0 for all z > 0. Now
f (z, 0) = B(PR− 1− D(1+ R))z− P
The sign of the z coefficient in this expression is not clear. However, we assume that (40) holds and so
substituting for D gives
f (z, 0) = −B(P(B− CR) + B+ C)
B+ C
z− P
which must be negative for all z > 0 using (41). Therefore, assuming that (40) and (41) hold, then329
f (z, e) 6= 0 for all e ∈ [0, 1) and so the infected branch of solutions does not blow up in our region of330
interest.331
5.3. Bifurcations (S = 0)332
We now consider bifurcations that occur in our equations with S = 0. In particular, there are333
bifurcations occurring when the branch of infected steady states intersects the uninfected branch and334
when it intersects the pure infection branch.335
5.3.1. Bifurcation on the Uninfected Branch336
Lemma 1.
With S = 0, there are two bifurcation points that occur on the uninfected branch of steady state
solutions (43) that each give rise to a bifurcating branch of infected steady state solutions. One
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bifurcation occurs for e > 1/α > 1, and so is out of our range of interest. The other bifurcation point
occurs at e = e0 < 1 where
e0

< 0 if BP < D(B+ C)
= 0 if BP = D(B+ C)
> 0 if BP > D(B+ C)
The uninfected branch is stable for e0 < e < 1 and unstable for e < e0.337
Proof.
The Jacobian matrix J(x, y, z) of Equations (29)–(31) (with S = 0) evaluated at the uninfected steady
state is given by
J(1, 0, 0) =
 −1 −1 −(1− αe)B0 −D (1− αe)B
0 (1− e)P −C− (1− αe)B
 (47)
Clearly one eigenvalue of this matrix is −1. We note that the remaining two eigenvalues must be real338
since, if they were complex, then y would oscillate around the steady state value y = 0 and similarly339
for z. However, by our invariance result (Theorem 1), this is not possible.340
A bifurcation point on the branch of uninfected steady states occurs when det J(1, 0, 0) = 0 which
gives
αBPe2 + (αD− (1+ α)P)Be+ BP− D(B+ C) = 0 (48)
If e = 1+ µ, then (48) expressed in terms of µ is given by
αBPµ2 + (αD− (1− α)P)Bµ− D(B(1− α) + C) = 0 (49)
We note that the constant term is negative (using (37)) and the µ2 coefficient is positive, and so the341
quadratic equation (49) has one positive and one negative solution. This implies that the two solutions342
of (48) must lie on opposite sides of e = 1 and so one bifurcation point occurs for e = e1 > 1 and the343
other for e = e0 < 1.344
A similar analysis with e = 1/α+ µ also shows that the two solutions in µ must have opposite345
signs, and this implies that e1 > 1/α > 1.346
Since e1 is always positive, the sign of the other solution e0 must match the sign of the constant347
coefficient of (48) since the coefficient of e2 is positive, as stated.348
To determine the stability of the uninfected branch, we need to know the signs of the three
eigenvalues of J(1, 0, 0). We have already noted that one eigenvalue is −1 and the remaining two
eigenvalues are found from the lower 2× 2 block in the Jacobian matrix, which we denote by J1. We
note that
tr(J1) = −C− D− (1− αe)B < 0
since αe < 1 (using (37), (38)) and
det(J1) = −αBPe2 − (αD− (1+ α)P)Be− BP+ D(B+ C)
The determinant is negative for e < e0 since the coefficient of e2 is negative. A negative determinant349
implies that the eigenvalues have opposite sign and so there is one positive and one negative eigenvalue350
which implies that the uninfected branch is unstable for e < e0.351
At the bifurcation point e = e0, there is one zero eigenvalue. We note that a double zero eigenvalue352
is not possible since the other bifurcation point occurs at e = e1 > 1/α. Thus, the determinant changes353
sign at e = e0 and so is positive for e0 < e < 1. A positive determinant and negative trace implies that354
both of the eigenvalues are negative and so the uninfected branch is stable in this range.355
Following our discussion regarding spontaneous clearance in Section 3.5, we note that the stability356
of the uninfected branch for our model agrees with that shown in Figure 2. We initially assume that the357
Viruses 2018, xx, x 18 of 41
bifurcation occurs precisely at e = 0 (Figure 2(b)), as this is the point between the two cases discussed.358
By Lemma 1, this occurs when BP = D(B+ C) and solving this for D gives the relation (40).359
We now consider the bifurcating branch of infected solutions that arises from the bifurcation point360
at e = 0.361
Lemma 2.362
When (40) holds, there is a transcritical bifurcation at e = 0 on the uninfected branch of solutions. The363
bifurcating branch of infected solutions is given by364
x = 1− c(BP+ B+ C)e+O(e2)
y = c(B+ C)e+O(e2)
z = cPe+O(e2)
where
c =
(1+ R)(B+ (1+ α)C)
(B+ C)(B− CR)− BCP(1+ R) (50)
This branch is unstable for e > 0 and stable for e < 0.365
Proof.366
To find the bifurcation equation, we solve (29)+(1+ R)(30) and (31) for x and y in terms of z and e367
which gives368
x = 1−
(
BP+ B+ C
P
)
z+ zO(z, e) (51)
y =
(
B+ C
P
)
z+ zO(z, e) (52)
Substituting these into (29) gives the bifurcation equation
c1ze+ c2z2 + zO((z, e)2) = 0 (53)
where369
c1 = −BP2(1+ R)(B+ (1+ α)C)
c2 = BP[(B+ C)(B− CR)− BCP(1+ R)]
The two quadratic terms are required for the normal form of a transcritical bifurcation [29]. The trivial
solution z = 0 of (53) corresponds to the uninfected branch. The nontrivial solution gives a low order
solution of the bifurcating infected branch which is given by
z = − c1
c2
e+O(e2) = cPe+O(e2)
Substituting this back into (51) and (52) gives the stated expansions for x and y in terms of e.370
With a transcritical bifurcation, the stability of the bifurcating branches is the opposite of the371
trivial solution and so, since the uninfected branch is stable for e > 0 (see Lemma 1), the bifurcating372
branch must be unstable for e > 0 and stable for e < 0.373
Clearly Lemma 2 can be generalised to the case of a bifurcation point occurring at e = e0 when374
(40) does not hold.375
We note that only one half of the bifurcating branch of infected solutions lies within our invariant376
regionR and this is the half for which ce > 0, since then y, z ≥ 0. In this case, we also have x ≤ 1 as377
we would expect. Referring back to Figure 2, we would like the valid half of the bifurcating branch378
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to occur for e > 0 and this occurs provided that c > 0. Clearly the numerator of c is positive, and379
assumption (39) ensures that the denominator is also positive so that c > 0. We then have precisely the380
situation sketched in Figure 2(b).381
Now if condition (40) is perturbed slightly, then the bifurcation point will occur for e either382
positive or negative. If it occurs for e < 0, then the uninfected steady state with no treatment (e = 0) is383
stable but with a nearby unstable steady state (Figure 2(a)). Conversely, if the bifurcation point occurs384
with e > 0, then the uninfected steady state with no treatment is unstable (Figure 2(c)).385
5.3.2. Bifurcation on the Pure Infection Branch386
In addition to the bifurcation involving the uninfected and infected branches of solutions, there is387
also a second bifurcation where the infected branch intersects the pure infection branch.388
Lemma 3.
With S = 0, there are two bifurcation points that occur on the pure infection branch of steady state
solutions (44) that each give rise to a bifurcating branch of infected steady state solutions. One
bifurcation occurs for e > 1/α > 1, and so is out of our range of interest. The other bifurcation point
occurs at e = e2 < 1 where
e2

< 0 if BP < CD(1+ R)(1+ D(1+ R))
= 0 if BP = CD(1+ R)(1+ D(1+ R))
> 0 if BP > CD(1+ R)(1+ D(1+ R))
The pure infection branch is stable for e < e2 and unstable for e2 < e < 1.389
Proof.390
The bifurcation points can be found by considering the Jacobian matrix derived from Equations391
(29)–(31) evaluated at the pure infection steady state. This matrix is lower triangular with diagonal392
entries given by393
J(xp, yp, zp(e))1,1 =
1
yp
− (1− αe)Bzp(e)− 1 (54)
J(xp, yp, zp(e))2,2 = − 1(1+ R)yp
J(xp, yp, zp(e))3,3 = −C
Since the matrix is lower triangular, these diagonal entries are the eigenvalues. Clearly the second
and third eigenvalues are negative. The bifurcation points therefore occur when J(xp, yp, zp(e))1,1 = 0
Substituting for yp and zp(e) from (44) gives the quadratic equation in e
p(e) = −BPαe2 + BP(1+ α)e+ CD(1+ R)(1+ D(1+ R))− BP = 0 (55)
If e = 1+ µ, then (55) expressed in terms of µ is given by
p(1+ µ) = −BPαµ2 + BP(1− α)µ+ CD(1+ R)(1+ D(1+ R)) = 0
Since the constant term is positive and the µ2 coefficient is negative, this quadratic equation has394
solutions of opposite sign which implies that the two solutions of (55) lie on opposite sides of e = 1.395
Clearly the bifurcation point e = e3 > 1 is out of our range of interest and so we now consider the396
other bifurcation point at e = e2 < 1.397
A similar analysis with e = 1/α+ µ also shows that the two solutions in µ must have opposite398
signs, and this implies that e3 > 1/α > 1.399
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Since e3 is always positive, the sign of e2 will be the opposite of the sign of the constant coefficient400
in (55), since the e2 coefficient is negative.401
The stability of the pure infection steady state is determined by the sign of J(xp, yp, zp(e))1,1 since402
the other two eigenvalues of J(xp, yp, zp(e)) are negative. Combining the two terms in (54) gives a403
rational function with a positive denominator. The sign is therefore determined by the numerator,404
which is the expression on the left hand side of (55). Since e2 < 1 < e3 and the coefficient of e2 is405
negative, then clearly J(xp, yp, zp(e))1,1 < 0 for e < e2 and so the pure infection steady state is stable406
in this range. There is no possibility of a double root occurring as the two roots lie on opposite sides of407
e = 1 and so this quadratic must change sign at the bifurcation point. Therefore, the pure infection408
solution is unstable for e2 < e < 1 as claimed.409
It is natural to assume that the pure infection state is stable when there is no treatment (e = 0)
and from Lemma 3, we see that this occurs provided that
BP− CD(1+ R)(1+ D(1+ R)) > 0 (56)
which implies that e2 > 0. However, we will show in Section 5.4.4 that this is in fact not required for
our later analysis of the model. We also note that with the assumption (40), the inequality (56) becomes
(B+ C)(B− CR)− BCP(1+ R)2 > 0
Clearly, this is very similar to the inequality in (39), but the fact that the last term is squared implies410
that the sign of this expression cannot be determined using (39) and so could be positive or negative.411
We now consider the bifurcating branch of infected solutions that arises from the bifurcation point412
at e = e2.413
Lemma 4.414
The bifurcating branch of infected solutions arising from the transcritical bifurcation on the pure415
infection branch at e = e2 is given by416
x = − c3
c4
(e− e2) +O((e− e2)2) (57)
y = yp + c5(e− e2) +O((e− e2)2)
z = zp(e2) +
(
c6 − PCyp
)
(e− e2) +O((e− e2)2)
= zp(e) + c6(e− e2) +O((e− e2)2)
where417
c3 = B
(
(1− αe2)
Pyp
C
+ αzp(e2)
)
c4 = (1− αe2)Bzp(e2)
(
(1− αe2)B
(
1
C
− (1+ R)zp(e2)
)
− R
yp
)
c5 = −((1− αe2)B(1+ R)ypzp(e2)− 1) c3c4
c6 = zp(e2)
(
(1− αe2)B
(
1
C
− (1+ R)zp(e2)
)
+
1
yp
)
c3
c4
This branch is stable for e > e2 and unstable for e < e2.418
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Proof.419
Since the pure infection steady state has x = 0, we will derive the bifurcation equation in terms of x420
and e− e2. To do this, we solve Equations (30) and (31) for y and z in terms of x and e− e2 which gives421
y = yp + ((1− αe2)B(1+ R)ypzp(e2)− 1)x+ xO(x, (e− e2)) (58)
z = zp(e2) + zp(e2)
(
(1− αe2)B
(
(1+ R)zp(e2)− 1C
)
− 1
yp
)
x
− P
C
yp(e− e2) +O((x, (e− e2))2) (59)
Substituting these into (29) gives the bifurcation equation
c3x(e− e2) + c4x2 + xO((x, (e− e2))2) (60)
where422
c3 = B
(
(1− αe2)
Pyp
C
+ αzp(e2)
)
c4 = (1− αe2)Bzp(e2)
(
(1− αe2)B
(
1
C
− (1+ R)zp(e2)
)
− R
yp
)
The two quadratic terms are required for the normal form of a transcritical bifurcation [29]. The trivial
solution x = 0 of (60) corresponds to the pure infection branch. The nontrivial solution gives a low
order solution of the bifurcating infected branch which is given by (57). Substituting for x back into
(58) and (59) gives the stated expansions for y and z in terms of (e− e2). We also note from the pure
infection steady states (44) that
zp(e2)− PCyp(e− e2) = zp(e)
and this is used to derive the stated second form of z.423
The stability of the bifurcating branches at a transcritical bifurcation is the opposite of the trivial424
solution and so, since the pure infection branch is stable for e < e2 (see Lemma 3), the bifurcating425
branch must be unstable for e < e2 and stable for e > e2.426
We note that c3 > 0 using (37) and the fact that e2 < 1 (see Lemma 3). However, c4 could be427
positive or negative depending on the values of the parameters in the model. Since x cannot be428
negative, we see from (57) that429
• if c4 < 0, then x(e) has positive slope and valid solutions exist locally only for e ≥ e2;430
• if c4 > 0, then x(e) has negative slope and valid solutions exist locally only for e ≤ e2.431
Also, if c4 > 0, then
(1− αe2)B
(
1
C
− (1+ R)zp(e2)
)
>
R
yp
and this implies that
c6 >
zp(e2)(1+ R)c3
c4yp
and so c6 > 0 also. However, if c4 < 0, then c6 could be positive or negative.432
The solutions of Equations (29)–(31) near to the bifurcation point are sketched in Figure 4 for the433
three possible cases associated with different signs of c4 and c6.434
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x z
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x z
Figure 4. Solutions near to the bifurcation involving the infected (red) and pure infection (blue)
branches. Solid lines indicate stable solutions while dashed lines represent unstable solutions. Top:
c4 > 0. Middle: c4 < 0, c6 < 0. Bottom: c4 < 0, c6 > 0.
5.3.3. The Infected Steady State Branch (S = 0)435
We have found that the infected steady state branch intersects both the uninfected and the pure436
infection branches of steady states at transcritical bifurcation points. We next consider what happens437
to the infected branch in between these two bifurcations.438
Theorem 4.
We assume that (39) and (40) hold and that
R >
√
2− 1
2
(61)
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0
z
(a) The infected branch for c4 > 0.
0
z
(b) The infected branch for c4 < 0, c6 < 0.
0
z
(c) The infected branch for c4 < 0, c6 > 0.
Figure 5. The pure infection (blue) and infected (red) steady state branches. Note that the dash-dot
lines indicate invalid solutions.
Then the bifurcation point at e = 0 on the uninfected branch of solutions and the bifurcation point439
at e = e2 on the pure infection branch of solutions are connected by a continuous branch of infected440
steady state solutions. There is a single limit point on this branch of infected solutions which occurs441
between the two bifurcations when c4 < 0 or after the bifucation on the pure infection branch when442
c4 > 0. The limit point occurs at e = e4 where e2 < e4 < 1/α. The three possible cases, associated with443
different signs of the coefficients c4 and c6, are shown in Figure 5.444
Remark445
We conjecture that Theorem 4 holds for all R > 0, so that condition (61) is unnecessary. However, we446
have been unable to prove this. Some evidence to support this conjecture is included in the proof.447
Condition (61) is not overly restrictive though as it implies that rI/rT < 2/(
√
2+ 1) = 0.8284.448
Proof.
Substituting for D using (40) into (46) we obtain an equation involving z and e to be solved for the
infected branch of solutions given by
g(z, e) = BCR(B+ C)(1− αe)2z2 + (BCP(1+ R) + (B+ C)(CR− B(1− αe))(1− αe)z
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+ eP(1+ R)((B+ C)(1− αe) + αC) = 0 (62)
To find limit points on the infected steady state branch [29], we must solve the two equations
g(z, e) = gz(z, e) = 0
and check the non-degeneracy conditions
gzz(z, e) 6= 0, ge(z, e) 6= 0 (63)
Since g(z, e) is quadratic in z, then clearly gz(z, e) is linear in z and the z coefficient is strictly positive.
Thus, the second equation can be solved for z and substituted back into the first equation which gives
the quadratic equation in e
A1e2 + B1e+ C1 = 0 (64)
where449
A1 = −αB(B+ C)2(4CPR(1+ R) + αB)
B1 = CP(1+ R)(2R(B+ (1+ α)C)− αB) + α(B+ C)(B− CR)
C1 = −((B+ C)(B− CR)− BCP(1+ R))2
The discriminant of the quadratic is given by
∆ = 16BC2PR(1+ R)(B+ C)2∆1∆2 (65)
where450
∆1 = BP(1+ R) + α(B− CR) (66)
∆2 = (B+ C)(αB+ R(B+ C))− αBCP(1+ R) (67)
We have assumed that (39) holds and this implies (41) also and this gives ∆1 > 0. We also note that ∆2
can be expressed as
∆2 = ((B+ C)2 − αBCP)R+ αB(B+ C− CP)
Assumption (39) implies that (42) holds which implies that the second term is positive. Moreover,451
(B+ C)2 − αBCP > (B+ C)CP− αBCP using (42)
= CP(B(1− α) + C)
> 0
using (37) and this implies that ∆2 > 0 also. Therefore, ∆ > 0 and so the quadratic equation (64) will452
have two distinct solutions. We therefore expect to have two limit points on the infected solution453
branch(es). Now gzz(z, e) = 2BCR(B+C)(1− αe)2 > 0 using (37), (38) and so the first non-degeneracy454
condition in (63) is satisfied. However, it is not easy to verify the second non-degeneracy condition.455
We now use a different approach to get further information regarding the infected solution branches456
which will also confirm the existence of two limit points.457
To get a more complete picture of the solutions, we substitute
z = z0 +
z1 + δz
e1 + δe
, e = e0 + e1 + δe (68)
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into (62). The parameters z0, z1, e0 and e1 can be solved for in terms of the parameters so that our
equation reduces to
h1δe2
h0
− h2δz
2
h0
= 1 (69)
where
z0 =
1
2CR
, z1 =
BP(1+ R) + R(B+ C)
2αBR(B+ C)
,
e0 =
1
α
, e1 = −C[αR(B+ C) + P(1+ R)(2R(B+ C(1− α)) + αB)]α(B+ C)(αB+ 4CPR(1+ R)) ,
h0 =
P(1+ R)∆1∆2
4BRh1
, h1 =
α(B+ C)(αB+ 4CPR(1+ R))
4CR
, h2 = α2BCR(B+ C)
Clearly h1, h2 > 0 and we showed above that ∆1, ∆2 > 0 and so h0 > 0 also. Thus, (69) is the equation
of a hyperbola and the two solution branches are given in parametric form by
δz(β) =
√
h0
h2
sinh β, δe(β) = ±
√
h0
h1
cosh β
These solutions exist for all δz and for |δe| ≥ √h0/h1. This gives rise to parametric solutions of
(62) given by
z(β) = z0 +
z1 + δz(β)
e1 + δe(β)
, e(β) = e0 + e1 + δe(β) (70)
Limit points on these branches occur when
de
dz
=
de/dβ
dz/dβ
= 0
Now β = 0 is the unique solution of the equation de/dβ = 0 and
dz
dβ
∣∣∣∣
β=0
=
√
h0/h2
e1 ±
√
h0/h1
For this derivative to be finite, we clearly require e1±
√
h0/h1 6= 0. Now e1 < 0 and so e1−
√
h0/h1 <
0 but it is possible that e1 +
√
h0/h1 = 0. However, we will show later that the right hand (+) branch
is outside our range of interest, and so it does not matter whether this quantity is zero or non-zero.
Thus, on the left hand (−) branch, we have
dz
dβ
∣∣∣∣
β=0
=
√
h0/h2
e1 −
√
h0/h1
6= 0
and so de/dz = 0 when β = 0. This point will be a quadratic limit point provided that the
non-degeneracy condition d2e/dz2|β=0 6= 0 is satisfied. It is a matter of calculation to show that
for the left hand branch
d2e
dz2
∣∣∣∣
β=0
=
d2e/dβ2
(dz/dβ)2
∣∣∣∣
β=0
= −
√
h2
h0h1
(
e1 −
√
h0/h1
)2 6= 0
again using the fact that e1 −
√
h0/h1 < 0, and so we do indeed have a quadratic limit point when
β = 0. Thus, the limit point on the left hand branch of solutions occurs at
z(0) = z0 +
z1
e1 −
√
h0/h1
, e(0) = e0 + e1 −
√
h0/h1
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and two solutions exist for each e < e(0), which is also confirmed by the negative second derivative.458
We note that there are no solutions of (69) when δe = 0 and this corresponds to e = e0 + e1. We
now show that e2 < e0 + e1 < 1/α. The right hand inequality is clearly satisfied since e0 = 1/α and
e1 < 0. To verify the left hand inequality, we consider the quadratic equation (55). We have already
shown in the proof of Lemma 3 that the two solutions e2 and e3 of this equation satisfy e2 < 1 < e3.
Since the coefficient of e2 is negative, this implies that the quadratic function p(e) is positive if and
only if e2 < e < e3. If p(e0 + e1) > 0, then this implies that e2 < e0 + e1 as required. It can be shown
that
p(e0 + e1) =
BPC(a3P3 + a2P2 + a1P+ a0)
α(B+ C)2(αB+ 4CPR(1+ R))2
(71)
where a0, a1, a3 > 0, using (37) and (41). The remaining coefficient, a2, is given by
a2 = C(1+ R)2(b2B2 + b1B+ b0)
where b0, b1 > 0 and
b2 = (8α2 − 8α+ 4)R2 + 4α2R− α2
Now b2 is negative for α > 0 and sufficiently small R. Substituting R = (
√
2− 1)/2+ R˜ into b2 gives
b2 = (8α2 − 8α+ 4)R˜2 + 4(2
√
2− 1)
7
(7α2 + (2
√
2− 6)α+ 3−
√
2)R˜+ (3− 2
√
2)(1− α)2
The first and second order coefficients of R˜ are positive and the constant coefficient is non-negative for459
all α ∈ [0, 1]. Thus, b2 > 0 for R˜ > 0 and for all α ∈ [0, 1], or equivalently, for all R > (
√
2− 1)/2. In460
this case, a2 > 0 also which then implies that p(e0 + e1) > 0 as required.461
Thus, we have proved that p(e0 + e1) > 0 using condition (61). However, even if b2 < 0, there
are still many other positive terms in p(e0 + e1) and so it may be the case that condition (61) is not
necessary. We note that the minimum of b2 in the region R ≥ 0, α ∈ [0, 1] occurs at R = 0, α = 1.
Substituting R = 0, α = 1 into the cubic polynomial in P in (71) gives
(a3P3 + a2P2 + a1P+ a0)|R=0,α=1 = B2(1+ P)(B+ C− CP)
Using assumption (42), this is positive. Moreover expanding the cubic polynomial in a Taylor series462
about the point (R, α) = (0, 1), we find that the first order terms are positive and so for sufficiently463
small R > 0 and α < 1, the cubic polynomial in P will be positive. However, this does not guarantee464
that it is positive for all R > 0 and α ∈ [0, 1], although we conjecture that this is in fact the case.465
Now the two branches of solutions (70) occur either side of the gap in e and so one branch exists466
for e < e0 + e1 and the other for e > e0 + e1. The left hand branch is therefore the only branch of467
infected solutions for e < e0 + e1 and so the two bifurcating branches of infected solutions arising468
from the two bifurcations described above must be part of this single branch.469
Thus, there is a single branch of infected solutions that connects the two bifurcation points, as470
claimed. There must also be a limit point on this branch which occurs for e > e2.471
The only steady state solutions with x = 0 are the uninfected or pure infection solutions. Thus, all472
other solutions, in particular the infected solutions, have x 6= 0. In the case of c4 > 0 (Figure 4 (top)),473
the only way that the valid infected branches arising from the two bifurcations can connect on a curve474
with a single limit point is for the limit point to occur on the invalid solutions after the bifurcation on475
the pure infection branch, as shown in Figure 5(a). When c4 < 0 (Figure 4 (middle, bottom)), the valid476
infected solution emanates from the pure infection branch to the right of the bifurcation point, and the477
only way that these can connect to the bifurcation on the uninfected branch at e = 0 is for there to be a478
limit point in between the two bifurcations.479
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We note that the left branch of (69) exists for all δz, but does not exist for all z. As δe → −∞
(β → ±∞), the left branch of the hyperbola asymptotes to the straight lines δz = ±√h1/h2 δe.
Substituting these into z(β) given by (70), we see that z converges to the constant values
z = z0 ±
√
h1/h2 =
1
2CR
(
1±
√
1+ 4CPR(1+ R)/(αB)
)
as e→ −∞. Clearly one of these asymptotes is negative and the other positive, as we would expect.480
Finally, we recall the assumption we made in Theorem 4 that D is defined by (40). If this is not the481
case, then the same method described above can be used to derive equation (69) and z0, e0, h1 and h2482
are unchanged. However, the other coefficients now involve the parameter D. In this case, it is not483
possible to determine the sign of the coefficient h0 in (69). As long as h0 remains positive, the same484
picture as described above will hold qualitatively. However, if h0 changes sign and becomes negative,485
then the structure of the solutions of (69) changes, so that there are no limit points occurring. So if486
(40) does not hold, then there is an extra condition h0 > 0 that is required to give the same solution487
structure.488
5.4. Steady States (S > 0)489
We have studied in detail the solutions of our model in the special case when S = 0, which is490
when there is no production of hepatocytes from stem cells. When S is small and positive, this will491
result in a small perturbation of these solutions and we now consider this case.492
5.4.1. Bifurcation on the Uninfected Branch493
When S > 0, the uninfected steady state (43) and the bifurcation point that is found by solving494
(48) between the uninfected and infected steady state branches both remain the same. Therefore, the495
condition (40) again ensures that this bifurcation point occurs at e = 0.496
5.4.2. Bifurcation on the Pure Infection Branch497
When S > 0, the state of pure infection no longer exists since there is a second mechanism for498
generating healthy hepatocytes due to stem cell production. Thus, for small values of S, the bifurcation499
involving the infected and pure infection branches will unfold. There are two possible ways that a500
transcritical bifurcation can unfold, depending on the sign of the perturbation term.501
When S > 0, the bifurcation equation (60) in x simply gains an extra term Sy where y is given by
(58) and so is given by
h(x, δe) = S(yp +O(x, x2, xδe)) + c3xδe+ c4x2 + xO(x, δe) (72)
where δe = e − e2. The constant term is the only term needed to determine the unfolding of a
transcritical bifurcation [29]. Limit points for this equation are found by solving h(x, δe) = hx(x, δe) =
0 and are then given by
x2 =
Syp
c4
+O(S2)
Since S > 0, we see that for sufficiently small S502
• if c4 < 0 then no limit points exist;503
• if c4 > 0, then there are two limit points at x = ±
√
Syp/c4.504
We recall that c3 > 0 and so the sign of c4 also determines the slope of the bifurcating branch (see505
Figure 4). The unfolding of the bifurcation in these two cases is shown in Figure 6. We note that when506
S > 0, in both cases one of the branches locally has x < 0 and one has x > 0 and so there is only one507
valid branch of solutions.508
When e2 > 0, the unfolding of the solutions in Figure 5 is shown in Figure 7.509
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S = 0 S > 0
S = 0 S > 0
Figure 6. Unfolding of the transcritical bifurcation given by (72) in the (e, x) plane for c4 > 0 (top) and
c4 < 0 (bottom).
5.4.3. Infected Branch of Solutions510
For the infected solution branch away from the bifurcation points, the Implicit Function Theorem511
implies that a small perturbation in the equations due to S > 0 results in an O(S) perturbation in512
the infected solutions and so there is only a small perturbation in this branch of solutions. Thus, we513
see that in all cases, the form of the infected steady states is qualitatively similar since the branch of514
infected states emanates from the trivial solution at the bifurcation point at e = 0 and increases with e,515
goes round a limit point and then decreases, as shown in Figure 7. Moreover, this is the only valid516
branch of infected steady state solutions.517
5.4.4. The Case of e2 < 0518
Finally, we consider one more situation, namely when condition (56) does not hold. Thus, we
now assume that
BP− CD(1+ R)(1+ D(1+ R)) < 0 (73)
This implies that e2 < 0 by Lemma 3 and so the bifurcation point on the pure infection branch with519
S = 0 occurs for negative e. The infected branch of solutions still has a limit point in this case but there520
is no connection between these two branches in our range of interest given by e ∈ [0, 1). Moreover, the521
pure infection steady state with no treatment (e = 0) is unstable, since condition (56) was required to522
ensure stability. In this case, the unfolding of the bifurcation when S > 0 occurs in the same way but523
outside our range of interest and the pure infection branch becomes invalid. The solutions in this case524
are shown in Figure 8. We note that the valid solution branch is similar in this case as in the previous525
cases considered, with a single limit point occurring.526
6. Stability527
All the cases considered above, with assumptions (39) and (40), give rise, when S > 0, to an528
uninfected steady state branch x = 1, y = z = 0 together with a branch of infected steady state529
solutions that bifurcates from e = 0 and has a single limit point. We have also seen that the uninfected530
branch of solutions is stable for e ∈ (0, 1) and this implies that the bifurcating branch of infected531
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(a) Steady state solutions for c4 > 0.
0
z
(b) Steady state solutions for c4 < 0, c6 < 0.
0
z
(c) Steady state solutions for c4 < 0, c6 > 0.
Figure 7. Steady state solutions where the bifurcation between the infected and pure infection branches
has been unfolded as S > 0, assuming that e2 > 0. The dash-dot lines are invalid solutions as x < 0.
solutions initially has one unstable eigenvalue together with two stable eigenvalues. The only way532
that the infected branch can become stable again is if the unstable eigenvalue passes back through zero,533
which would correspond to a limit point. We have also ascertained that there is precisely one limit534
point on the branch of infected solutions (for sufficiently small S). Since the solutions past the limit535
point are stable when S = 0, they will still be stable for small S > 0 and so the one unstable eigenvalue536
must pass through zero at the limit point to give a stable branch of solutions. Thus, the bifurcation537
diagram for S > 0 (and sufficiently small) is as shown in Figure 9(a).538
The other possibility is that the two stable eigenvalues along the unstable section of the infected539
branch could collide and become complex and then cross the imaginary axis in a Hopf bifurcation.540
They would then have to cross back again in a reverse Hopf bifurcation before the limit point in order541
for the solution to stabilise after going round the limit point. However, to determine whether or not542
such Hopf bifurcations occur analytically from the model is a very challenging problem. It is also of543
little interest, since any bifurcating periodic orbits would be unstable.544
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Figure 8. The steady state solutions when (73) holds and S > 0. The dash-dot line consists of invalid
solutions as x < 0.
7. Comparison with the Neumann/Dahari Models545
We now compare the predictions from our new model of HCV infection with those of the546
Neumann and Dahari models that we reviewed in Section 2. Our model is similar to previous models547
in that it involves the three variables T, I and V. However, the steady state solutions, and therefore548
the dynamics, of the new model are quite different from previous models in several ways. These549
differences result in different predictions for the dynamics of the infection during treatment and550
suggest possible different treatment regimes.551
A typical bifurcation diagram for the Neumann/Dahari models is shown in Figure 10(a) which552
we compare with the bifurcation diagram for our model as shown in Figure 9(a). We also note553
that experimental data is plotted with log10 V on the vertical axis rather than V, and so we also554
show the bifurcation diagrams plotted for log10 z in Figs 9(b), 10(b). We also note from (26) that555
log10 V = log10 z + k where k = log10(rTTmax/(rT + d)) and so the non-dimensionalisation only556
results in a shift on the vertical axis.557
We now make a number of comparisons between these models.558
• For the Neumann/Dahari models, treatment will only be effective once the treatment factor e559
exceeds a critical value determined by the bifurcation point, regardless of the viral load when560
treatment commences. For our model, if the viral load is close to the infected steady state561
before treatment starts, then similarly the treatment factor e must exceed the critical value eLP562
determined by the limit point for the treatment to be effective. However, if the infection is caught563
and treated in the early stages, while the viral load is still relatively low, then our model predicts564
that a lower drug dose, with a corresponding smaller value of the treatment parameter e, will be565
effective.566
• As mentioned previously, once treatment is stopped, the prediction of the Neumann/Dahari567
models is that the infection will take hold again unless the infected hepatocytes and virus have568
been completed eliminated during treatment. The prediction from our model, if the bifurcation569
point on the uninfected solution branch occurs at a negative value of e (e0 < 0), is that the body570
will be able to eliminate a small amount of infected hepatocytes and virus cells without further571
treatment once their levels have been reduced sufficiently. On the other hand, if the bifurcation572
point on the uninfected branch occurs at a positive value of e (e0 > 0), then our model predicts573
in this case that the infection will take hold again on cessation of treatment unless the infected574
hepatocytes and virus cells have been completely eliminated during treatment. However, our575
model also predicts that continuing with a low level of drug treatment, corresponding to a small576
value of e, will stop the infection recurring in this case.577
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Figure 9. The bifurcation diagram, where solid lines indicate stable solutions and dashed lines indicate
unstable solutions. Note that the vertical scale is either (a) z or (b) log10 z.
• The Neumann/Dahari models suggest that treatment will only be effective if the treatment578
parameter e is greater than the critical value during the whole period of treatment, which is the579
way that patients are generally treated in practice. Our model suggests that the drug dose could580
be reduced as treatment progresses and that this will still be effective, provided that it is not581
reduced too far too quickly. If this is indeed the case, it could save some of the costs of treatment582
and a lower drug dosage may also mean a reduction in side effects, which would benefit the583
patient.584
8. Description of Observed Viral Load Profiles585
The usual approach with a new model is to fit it to data in order to show that there are values of586
the model parameters that give a good fit to this data. This is a useful approach, but does not give587
any insight into the mechanisms involved in the different cases. Thus, we now consider many of the588
observed behaviours of the viral load under treatment that are reported in the literature and show589
how our model can explain these observations. This also helps to explain the possible mechanism590
associated with the observations in some cases. In the next section, we then fit our model to four591
datasets to show that this can also be done in practice.592
A number of different viral load profiles were reported in [24], and we first consider these.593
However, we also consider various other observations in the literature. In this section, we define594
e∗ ∈ (0, 1) to be the value of the treatment parameter in the model, which may of course vary for595
different patients.596
8.1. Sustained Virologic Response (SVR)597
Sustained virologic response is where the viral load rapidly decreases and is undetectable at the598
completion of treatment at 24 weeks [24]. For our model, this is easily realised by having eLP < e∗ so599
that the trajectory in our model converges to the only available uninfected steady state, which is stable600
provided that e0 < e∗. To see this rapid one phase decline, it is likely that treatment commenced not601
too long after infection, since a delay in treatment is often associated with biphasic or triphasic decline602
of the viral load (see Section 8.6). Once treatment is stopped, the viral load remains undetectable,603
and this will be the case provided that e0 < 0, or equivalently BP < D(B+ C) (see Lemma 1 and the604
discussion in Section 3.5).605
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Figure 10. A typical bifurcation diagram for the Neumann/Dahari models, where solid lines indicate
stable solutions and dashed lines indicate unstable solutions. Note that the vertical scale is either (a) z
or (b) log10 z.
8.2. Relapse606
Relapse is similar to SVR during treatment, in that there is a rapid decline in viral load. However,607
once treatment stops, the patient relapses as the viral load increases back to pre-treatment levels. This608
relapse occurs if e0 > 0 as discussed in Section 3.5. In this case, continuing with a lower drug dose609
may be sufficient to keep the viral load under control.610
8.3. Partial Virologic Response (PVR)611
There is partial virologic response if an initial decrease in viral load is followed by an increase612
during treatment. This could be explained by our model if e∗ < eLP and with the viral load quite high613
before the start of treatment. In this case, the trajectory of the model would converge to the infected614
steady state at e∗ and it is quite possible that it could initially overshoot this steady state and then615
return back to it.616
8.4. Breakthrough617
Breakthrough is similar to PVR, except that at some point during treatment the viral load is618
undetectable before increasing again during treatment. Thus, the mechanism would be similar to that619
described for PVR but with the infected steady state occurring at a lower viral load so that there is a620
larger initial drop in the viral load, below the level of detection, before increasing again back up to the621
infected steady state.622
8.5. Null Response623
Some patients show no significant reduction in viral load under treatment. This could occur when624
e∗ < eLP and where the infected steady state at e∗ is similar to that at e = 0. This could occur when625
c4 < 0 and c6 > 0, as shown in Figure 7(c).626
8.6. Biphasic and Triphasic Decline627
A common observation of the viral load during treatment is that there is biphasic decline [4],628
although triphasic decline, with a flat region between two declining phases, has also been observed629
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[4,5]. We now show that both these patterns of decline in the viral load under treatment can occur in630
our model.631
We assume that S, the parameter associated with generation of hepatocytes due to stem cells, is632
small (and positive). When there is no treatment (e = 0), the infection steady state is then given by633
x =
C
BP− CD(1+ R)(1+ D(1+ R))S+O(S
2)
y = yp +O(S)
z = zp(0) +O(S)
where yp and zp(0) are the pure infection steady states given by (44). We assume that (56) holds so634
that this solution is both valid (as x > 0) and stable.635
If we assume that a patient has been infected for a long time before treatment, then this implies636
that at the start of treatment x(0), y(0) and z(0) will be close to these steady state values. We therefore637
now assume that x = O(S) and so we set x = Sx˜. Substituting for x in (29)–(31) and taking only the638
leading order terms in S gives the reduced equations639
x˜′ = y+ x˜
y
− x˜− (1− αe)Bx˜z (74)
y′ = 1
1+ R
(1− y)− Dy (75)
z′ = (1− e)Py− Cz (76)
We note that equation (75) is a linear equation in y with stable steady state y = yp. Since we are640
assuming that y(0) is close to this steady state, dynamically y will continue to converge towards the641
steady state and is not influenced by either x or z.642
Equation (76) has the stable steady state z = zp(e). Once treatment starts with e = e∗, this steady
state drops from zp(0) to zp(e∗) = (1− e∗)zp(0). Since y is approximately constant, this implies at the
start of treatment that z will decay exponentially towards the new steady state value. If we assume
that y = yp, then the solution of (76) is
z = zp(e∗) + (z(0)− zp(e∗))e−Ct (77)
This is the observed first phase of rapid decline in the viral load. We note that equation (74) can be
written as
x˜′ = y+ x˜
y
− x˜− Bx˜z+ (αBx˜z)e
Thus, the effect of increasing e at the start of treatment is to increase x˜′ and this will result in x˜643
increasing also.644
Once z has dropped to close to the steady state zp(e∗), and assuming that y is also close to yp,645
then y′ = O(S) and z′ = O(S) and so y and z evolve on a slow timescale. Thus, they will remain646
approximately constant for a time of O(1/S). This is the flat middle phase in the triphasic decline.647
Eventually, the O(S) terms in the y and z equations will result in y and z being displaced from
their leading order steady states, and the third phase decline towards the uninfected steady state will
start. This rate of decline is determined by the eigenvalue of the Jacobian matrix evaluated at the
uninfected steady state given in (47) that is closest to zero. Clearly one eigenvalue is λ1 = −1, and this
is unlikely to be the closest to zero. The other two eigenvalues are found from the lower 2× 2 matrix.
The characteristic equation which has to be solved for these eigenvalues is given by
p(λ) = λ2 + ((1− αe)B+ C+ D)λ− BP(1− e)(1− αe) + D((1− αe)B+ C) = 0 (78)
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Assuming that e∗ > e0, then the uninfected steady state is stable and so the two solutions of this
characteristic equation are both negative. Suppose that these solutions are −λ1 and −λ0 with −λ1 <
−λ0 < 0. In this case, the rate of decline to the uninfected steady state is determined by the eigenvalue
closest to zero which is −λ0. The third phase decline is generally observed to be slower than the first
phase and this will be the case if C > λ0. Now p(λ) < 0 if and only if −λ1 < λ < −λ0. Thus, if
p(−C) < 0, then this implies that −C < −λ0 as required. Now
p(−C) = −(1− αe∗)B(C+ (1− e∗)P− D)
Clearly, this is negative if C+ (1− e)P > D and so this is the condition that ensures that the third648
phase decline is slower than the first phase.649
Thus, we have shown that our new model can exhibit triphasic decline of the viral load, as650
is seen in the data. This analysis also suggests that this pattern of decline is associated with late651
commencement of treatment so that the initial conditions for the model are close to the infected steady652
state. This is also the conclusion reached by Dahari et al. [4].653
Biphasic decline is similar to triphasic decline, but where the middle flat phase is very short. The654
first order term in S in Equations (75) and (76) is ±S(1− αe∗)Bx˜z and so anything that increases the655
magnitude of this term will reduce the length of the middle phase. This includes a larger value of S or656
B or a larger value of zp(e∗). We note that an increase in B will also result in a more rapid increase in x657
which will also help to shorten this phase. Thus, our model can also exhibit biphasic decline of the658
viral load.659
8.7. Initial Increase in Viral Load660
Hsu et al. [15] reported that in some patients there is an initial increase in viral load when661
treatment is started, and that this initial increase is associated with a higher likelihood of achieving662
SVR. They used different models to investigate this behaviour and concluded that a modification of663
the Neumann model gave the best fit provided that c = δ and η = 1, which implies that the treatment664
always provides a complete block on de novo infection. Guedj et al. [12] questioned these unrealistic665
assumptions and the analysis in [15], and suggested that the initial increase in viral load was due to666
the infected steady state not having been reached so that viral loads were increasing before the start667
of therapy. They also suggested that the correlation between the initial increases and SVR was an668
indication of the effectiveness of the therapy. Rong and Perelson [23] also considered this effect in their669
multiscale model for direct acting antiviral agents. Their model always showed a small initial increase670
in viral load, even when starting from steady state. Of course this result cannot be directly compared671
with the experimental results of Hsu et al. [15] since these results were obtained for patients treated672
with IFN and RBV only.673
To understand this effect from our model, we express (31) as
z′ = Py− Cz− Bxz− e(Py− αBxz) (79)
Without treatment (e = 0), we expect z to be increasing towards the infected steady state and so z′ > 0
which implies that
Py− Cz− Bxz > 0 (80)
We note that
Py− αBxz = (Py− Cz− Bxz) + (Cz+ (1− α)Bxz) > 0
assuming that (80) holds, and using (37).674
If we assume that the infected steady state (xi, yi, zi) has been reached before the start of treatment,
then at t = 0 we have
z′(0) = −e∗(Pyi − αBxizi) = −e(Czi + (1− α)Bxz)
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which is negative, and so we have an immediate decline in viral load. However, if the steady state has
not been reached before treatment commences, then with (x, y, z) = (x(0), y(0), z(0)) at the start of
treatment, we have
z′(0) = Py(0)− Cz(0)− Bx(0)z(0)− e∗(Py(0)− αBx(0)z(0))
which is the difference of two positive terms, and so could be negative or positive. Larger values of e∗675
are more likely to give z′(0) < 0, and so effectiveness of treatment does not explain the correlation676
between the initial increase and SVR, as suggested in [12]. We propose an alternative explanation for677
this correlation.678
Soon after infection, the viral load will be increasing rapidly while y and z are both quite small,679
and so the effect of the treatment will be small also so that z′(0) > 0, thus giving an initial increase in680
viral load. However, if the start of treatment is delayed and the system is getting towards the infected681
steady state, then z′(0) will be quite small before treatment commences. However, near to the steady682
state, Py(0) will be relatively large, so that the net effect gives z′(0) < 0 once treatment starts. Thus,683
according to this model, an initial increase in viral load is associated with early initiation of treatment,684
which is likely to correlate with a higher rate of SVR, as reported in [15].685
8.8. Direct Acting Antiviral Agents686
Recently, new direct acting antiviral (DAA) agents have become available, which are more effective687
than treatment with IFN and RBV alone. If DAA’s are used as a monotherapy, then it is found that688
drug resistant virus cells quickly form, rendering the treatment ineffective and so they are used in689
combination with IFN and RBV, and this combination is found to be highly effective [6]. More complex690
models for the action of DAA’s have been proposed [21]. It has been found that treatment which691
includes DAA’s has notable differences compared to treatment with only IFN and RBV which include692
(i) a more rapid and longer first phase decline and (ii) a more rapid second phase decline [6].693
We note that the action of a DAA is essentially to further block viral replication, although by694
different mechanisms than the older drugs [27]. The simplest way that this can be modelled is to695
increase the parameter e in (31). If it is also assumed that the DAA’s do not have any additional effect in696
reducing the rate of production of infected cells (parameter η in Equations (19)–(21)), then an increase697
in e must be accompanied by a corresponding reduction in the parameter α given in (27), in order to698
keep η = 1− αe > 0 constant. We claim that this simple change is sufficient to explain both of the699
above observed effects, which we now justify.700
(i) It has been noted that the first phase decline when treating with DAA’s is both longer and faster701
than when using IFN and RBV. Since the rate of the first phase decline is essentially given by the702
parameter C (or c for the original equations), it has been suggested that both e and c should be703
increased in the models for treatment with DAA’s [6]. However, we claim that an increase in e704
alone is sufficient to produce a longer and faster first phase. To see this, we consider the decline705
in viral load during the first phase that is given in (77). For this solution, we find that the initial706
rate of decline is707
d(log10 z)
dτ
∣∣∣∣
τ=0
= −
(
1− zp(e
∗)
zp(0)
)
C log10 e
= −e∗C log10 e
since zp(e∗) = (1− e∗)zp(0), and so the initial slope increases as the treatment factor e∗ increases,708
with maximum slope only being achieved when e∗ = 1 (which corresponds to zp(e∗) = 0).709
Clearly, the steady state zp(e∗) is also reduced as e∗ is increased. These two effects result in an710
increase in the length of the decline in the viral load together with more rapid decline. This is711
illustrated in Figure 11.712
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Figure 11. The decline in viral load given by (77) with zp(0) = 1, C = 1 and zp(e∗) = 0.5 (blue) or
zp(e∗) = 0.2 (red).
(ii) The second observation made for DAA’s is that the second phase is also faster than that for
treatment with IFN and RBV. We have seen in Section 8.6 that for our model the rate of decay
in the second phase is proportional to e−λ0t where −λ0 < 0 is the solution of the characteristic
equation (78) that is closest to zero. With our assumption that η = 1 − αe is constant, (78)
becomes
p(λ(e)) = λ(e)2 + (ηB+ C+ D)λ(e)− ηBP(1− e) + D(ηB+ C) = 0 (81)
Differentiating this equation with respect to e and solving for λ′(e) gives
λ′(e) = − ηBP
(ηB+ C+ D+ 2λ(e))
and evaluating at e = e∗ gives
λ′(e∗) = − ηBP
(ηB+ C+ D− 2λ0) (82)
for λ(e∗) = −λ0. The sign of the denominator is not clear. However, substituting λ = −(ηB+
C+ D)/2 into p(λ) given by (81) gives
p
(
−1
2
(ηB+ C+ D)
)
= −
(
(1− e)ηBP+ 1
4
(ηB+ C− D)2
)
< 0
using (38) and the assumption that η > 0. The quadratic coefficient of λ(e) in (81) is positive and
so p(λ(e)) is only negative between the two roots −λ1 and −λ0 which implies that
−λ1 < −12 (ηB+ C+ D) < −λ0
It follows from this that the denominator of (82) is positive, and so λ′(e∗) < 0. Hence, if e is713
increased from e∗, then the eigenvalue −λ0 will decrease to first order, thereby increasing the714
rate of the second phase decline.715
Thus, the observed effects of direct acting antiviral agents, in association with IFN and RBV, can716
be included in our model by simply keeping 1− αe constant and reducing e.717
9. Data Fitting718
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We claimed in Section 8 that our new model is capable of generating many of the observed profiles719
of viral load under treatment. We now fit our model to some data in order to demonstrate that this is720
indeed the case.721
For this data fitting, we use the model equations in dimensional form given by (19)–(21). We first722
note that it is not possible to fit all of the parameters in the model. In particular, the parameters η and723
β always occur in the combination (1− η)β and so, during treatment, we can only hope to determine724
this single quantity from the data. Similarly, e and p occur in the combination (1− e)p and so again725
we can only determine this single quantity during treatment.726
We also observe that the 5 parameters rT , rI , Tmax, d and δ occur only in the 4 groups rTTmax,727
rITmax, rT + d, rI + δ and so it will not be possible to identify all 5 of these parameters from the728
data. Instead of using these four parameter groups, we use rTTmax, rT + d, R and D, where R and D729
are non-dimensional parameters defined in (32). We write the Equations (19)–(21) in terms of these730
parameters as731
T˙ = sI +
rTTmaxT
T + I
− (rT + d)T − β∗VT (83)
I˙ =
1
1+ R
(
rTTmax I
T + I
− (rT + d)I
)
− D(rT + d)I + β∗VT (84)
V˙ = p∗ I − cV − β∗VT (85)
where
β∗ = (1− η)β, p∗ = (1− e)p
Values of the parameter groups rTTmax and rT + d will be found by fitting the model to data. We note732
that by including the non-dimensional parameter R, and requiring it to be positive, ensures that the733
conditions 0 < rI/rT < 1 are satisfied. Moreover, requiring D > 0 is consistent with the conditions734
rI < rT and d < δ, but does not guarantee that they hold. We also note that it is not possible to735
determine whether condition (39) holds since the parameter β cannot be determined. The sign of736
e0, the value of e at which the bifurcation on the uninfected branch occurs (see Lemma 1), cannot be737
determined either since β and p cannot be determined.738
The initial value V(0) will be taken from the data and the other initial values, T(0) and I(0), will739
be regarded as unknown parameters. Thus, there are a total of 10 parameters and initial values to be740
found by fitting the model Equations (83)–(85) to the data, all of which are required to be positive.741
We considered various datasets that show partial virologic response (PVR), breakthrough, null742
response and triphasic behaviour. The first three datasets are taken from [24] while the last one is743
taken from [14]. We fitted our model to the data during treatment only. The data together with the744
fitted curve V(t) and the predicted curves T(t) and I(t) from the model for each case are shown in745
Figure 12. The parameter values used are given in Table 1. These should not be regarded as definitive746
parameter values since very similar fits to the viral load data can be found using quite different sets of747
parameters values.748
We did not consider data that shows sustained virologic response (SVR) since these datasets749
typically contain only two data points before the viral load goes below the lower limit of quantification750
(see [24]), and there will be many parameter combinations that will fit the two data points. The model751
can of course show this behaviour for appropriate parameter values.752
For the breakthrough data, we note that the three lowest data points are recorded as 50IU/ml,753
which is the lower limit of quantification, and so the actual values of the viral load will be lower than754
this. However, we do not know the correct values of the viral load and so for the data fitting we kept755
the outer two of these values but ignored the middle value.756
We now make a number of observations regarding these results.757
• In the PVR, breakthrough and triphasic cases, we have I(t) < V(t) for all t, but in the null758
response case, I(t) is significantly higher than V(t).759
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Figure 12. Plots of the viral load V (blue), healthy hepatocytes T (green) and infected hepatocytes I
(red) against time fitted to the viral load datasets for (a) PVR, (b) breakthrough, (c) null response, (d)
triphasic.
• The initial viral load is highest in the PVR case, and we predicted in Section 8.3 that PVR would760
be associated with a high initial viral load.761
• In the null response case, it is interesting to observe that the fitted viral load V and infected762
hepatocyte concentration I both reduce towards zero, but very slowly. The start of the decline763
in these variables can be observed from around 300 days in Figure 12(c). At 1000 days after the764
start of treatment, the predicted values are log10 I(1000) = 5.1202 and log10 V(1000) = 2.8515.765
• In Section 8.6, we stated that triphasic decline might be expected when the patient has been766
infected for a long time before treatment, which means that the viral load will be high while the767
healthy hepatocyte concentration will be very low. This is precisely the situation observed in768
Figure 12(d).769
• In Section 8.7, we showed that an initial increase in viral load at the start of treatment is possible,770
and we see this in the null response case.771
• We saw in Section 3.1 that the regeneration rate for a healthy liver is 1.15× 10−2 for females and772
1.11× 10−2 for males. This is effectively the parameter rT + d in our new model. The value of773
this parameter when fitted to data is a little lower than this for the PVR and breakthrough cases774
and is slightly higher in the null response and triphasic cases.775
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Table 1. Parameter values for fitting the model to the data.
PVR Breakthrough Null Response Triphasic
s 1.1178× 10−1 1.5104× 10−4 4.6260× 10−3 3.1259× 10−3
rTTmax 1.0645× 104 2.8556× 104 1.2920× 106 1.1149× 102
rT + d 1.9927× 10−3 2.9890× 10−3 3.8518× 10−2 1.7882× 10−2
R 3.0078× 101 1.1686× 103 2.6011 2.0350× 10−1
D 5.8954× 101 5.7302× 102 1.1064 1.0962× 101
β∗ 8.3376× 10−9 7.1149× 10−9 1.9493× 10−7 3.3281× 10−8
p∗ 2.0396× 102 9.4025× 101 3.4868× 10−2 1.1646× 103
c 1.7908× 101 3.3659 2.7784× 10−4 1.4294
T(0) 3.3246 8.2935× 106 1.7755× 104 1.9948
I(0) 4.1752× 105 9.5880× 103 1.4523× 106 1.0355× 102
• The condition (33) for the solution to be bounded for all t ≥ 0 in terms of the parameters we are
using here is given by
min(s, p∗)(1+ R)− (rT + d)(1+ D(1+ R)) < 0
The term on the LHS for each of the fits to the data is given by PVR: −0.1790; Breakthrough:776
−2003; Null Response: −0.1753; Triphasic: −0.2500. All of these values are negative which777
ensures that each of the solutions exists and is bounded for all time by Theorem 3.778
10. Conclusions779
We have proposed a new mathematical model of HCV infection which involves the same three780
variables (concentrations of healthy and infected hepatocytes and of virions) as the models of Neumann781
and Dahari, but which has significantly different structure to the steady state solutions. The typical782
bifurcation diagram for our model is shown in Figure 9 and consists of an uninfected steady state783
branch with a bifurcating branch of infected steady state solutions on which there is a single limit point.784
Allowing the bifurcation point to occur at positive or negative values of the treatment parameter means785
that the model can include spontaneous clearance as well as relapse at the end of treatment. In the case786
S = 0 (no generation of hepatocytes from stem cells) we showed that there is a pure infection branch of787
solutions and an infected steady state branch was found analytically that connects the uninfected and788
pure infection branches. When S > 0, the bifurcation between the pure infected and infected branches789
unfolds, generating a single branch of infected solutions on which there is a limit point (see Figure 7).790
We have been able to describe these solutions of the model using only the assumption (39) and the791
requirement that the quantity BP− D(B+ C) is close to zero.792
We have shown in Section 8 that our model is able to show the many profiles of viral load reported793
in the literature, and the model has been fitted to four datasets in Section 9. Moreover, based on794
the bifurcation diagram shown in Figure 9 for our model, we also made some predictions regarding795
treatment (see Section 7) which we summarise as follows:796
• If the infection is caught and treated in the early stages, then our model predicts that a lower797
drug dose may be effective in eliminating the infection.798
• If the viral load relapses on cessation of treatment, then continuing with a low level of drug799
treatment may keep the viral load low.800
• The infected branch from the bifurcation on the uninfected branch to the limit point has positive801
slope and this suggests that the drug dose could be reduced as treatment progresses, which802
could save some of the costs of treatment and give a reduction in side effects for the patient.803
The Neumann HCV model was obtained by modifying earlier models for HBV and HIV infections.804
It would now be interesting to see whether this process could be reversed by adapting this new model805
for HCV infection for other viral infections.806
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Another avenue of interest would be to fit this model to viral load data while a patient is on807
treatment in order to make patient-specific recommendations from the model regarding the future808
treatment plan. An important step in this process would be to determine the feasibility of estimating809
each of the parameters in the model, as has been done for other HCV models [2].810
Acknowledgments: I am grateful to many colleagues for helpful conversations regarding mathematical modelling811
of HCV infection, including Piet van der Graaf, Mark Ransley, Edwin Rwemigabo, Hien Tran, Tom Banks, Joseph812
Arthur, Aluisio Seguardo, Cássia Mendes Corrêa, João Renato Rebello Pinho and Bernadette Moore.813
References814
1. B.M. Adams, H.T. Banks, M. Davidian, H.D. Kwon, H.T. Tran, S.N. Wynne and E.S. Rosenberg. HIV dynamics:815
Modeling, data analysis, and optimal treatment protocols. J. Comp. Appl. Math. 184, 10–49, 2005.816
2. J.G. Arthur, H.T. Tran and P.J. Aston. Feasibility of parameter estimation in hepatitis C viral dynamics models.817
J. Inverse Ill-Posed Probl. 25, 69–80, 2017.818
3. H. Dahari, M. Major, X. Zhang, K. Mihalik, C.M. Rice, A.S. Perelson, S.M. Feinstone and A.U. Neumann.819
Mathematical modeling of primary hepatitis C infection: Noncytolytic clearance and early blockage of virion820
production. Gastroenterology 128, 1056–1066, 2005.821
4. H. Dahari, A. Lo, R.M. Ribeiro and A.S. Perelson. Modelling hepatitis C virus dynamics: Liver regeneration822
and critical drug efficacy. J. Theor. Biol. 247, 371–381, 2007.823
5. H. Dahari, R.M. Ribeiro and A.S. Perelson. Triphasic decline of hepatitis C virus RNA during antiviral therapy.824
Hepatology 46, 16–21, 2007.825
6. H. Dahari, J. Guedj, A.S. Perelson and T.J. Layden. Hepatitis C viral kinetics in the era of direct acting antiviral826
agents and IL28B. Curr. Hepat. Rep. 10, 214–227, 2011.827
7. H. Darwiche and B.E. Petersen. Biology of the adult hepatic progenitor cell: “Ghosts in the machine”. Prog.828
Mol. Biol. Transl. Sci. 97, 229–249, 2010.829
8. S. DebRoy, B.M. Bolkerzand and M. Martcheva. Bistability and long-term cure in a within-host model of830
hepatitis C. J. Biol. Sys. 19, 533-550, 2011.831
9. W.L. Ferrar. Higher Algebra, Oxford University Press, Oxford, 1950.832
10. Global Hepatitis Report 2017. Geneva: World Health Organization, 2017.833
11. R. Grimshaw. Nonlinear Ordinary Differential Equations, Blackwell, Oxford, 1990.834
12. J. Guedj, H. Dahari and A.S. Perelson. Understanding the nature of early HCV RNA blips and the use of835
mathematical modeling of viral kinetics during IFN-based therapy. Proc. Nat. Acad. Sci. 108, E302,2011.836
13. Hepatitis C Fact Sheet. World Health Organization, 2017. http://www.who.int/mediacentre/factsheets/fs164/en/837
14. E. Herrmann, J.H. Lee, G. Marinos, M. Modi and S. Zeuzem. Effect of ribavirin on hepatitis C viral kinetics in838
patients treated with pegylated interferon. Hepatology 37, 1351–1358, 2003.839
15. C.S. Hsu, S.J. Hsu, H.C. Chen, T.C. Tseng, C.H. Liu, W.F. Niu, J. Jeng, C.J. Liu, M.Y. Lai, P.J. Chen, J.H. Kao840
and D.S. Chen. Associate of IL28B gene variations with mathematical modeling of viral kinetics in chronic841
hepatitis C patients with IFN plus ribavirin therapy. Proc. Nat. Acad. Sci. 108, 3719–3724, 2011.842
16. A. Katoonizadeh, F. Nevens, C. Verslype, J. Pirenne and T. Roskams. Liver regeneration in acute severe liver843
impairment: a clinicopathological correlation study. Liver Int. 26 1225–1233, 2006.844
17. A. Marshall, S. Rushbrook, S.E. Davies, L.S. Morris, I.S. Scott, S.L. Vowler, N. Coleman and G. Alexander.845
Relation between hepatocyte G1 arrest, impaired hepatic regeneration, and fibrosis in chronic hepatitis C846
virus infection. Gastroenterology 128, 33–42, 2005.847
18. A.U. Neumann, N.P. Lam, H. Dahari, D.R. Gretch, T.E. Wiley, T.J. Layden and A.S. Perelson. Hepatitis C viral848
dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 282, 103–107, 1998.849
19. E.A. Pomfret, J.J. Pomposelli, F.D. Gordon, N. Erbay, L.L. Price, W.D. Lewis and R.L. Jenkins. Liver850
regeneration and surgical outcome in donors of right lobe liver grafts. Transplantation 76, 5–10, 2003.851
20. T.C. Reluga, H. Dahari and A.S. Perelson. Analysis of hepatitis C virus infection models with hepatocyte852
homeostasis. SIAM J. Appl. Math. 69, 999-1023, 2009.853
21. L. Rong, J. Guedj, H. Dahari, D.J. Coffield Jr, M. Levi, P. Smith and A.S. Perelson. Analysis of hepatitis C virus854
decline during treatment with the protease inhibitor danoprevir using a multiscale model. PLOS Comp. Biol.855
9, e1002959, 2013.856
Viruses 2018, xx, x 41 of 41
22. L. Rong and A.S. Perelson. Treatment of hepatitis C virus infection with interferon and small molecule direct857
antivirals: viral kinetics and modeling. Crit. Rev. Immunol. 30, 131–148, 2010.858
23. L. Rong and A.S. Perelson. Mathematical analysis of multiscale models for hepatitis C virus dynamics under859
therapy with direct-acting antiviral agents. Math. Biosci. 245, 22–30, 2013.860
24. E. Snoeck, P. Chanu, M. Lavielle, P. Jacqmin, E.N. Jonsson, K. Jorga, T. Goggin, J. Grippo, N.L. Jumbe and N.861
Frey. A comprehensive hepatitis C viral kinetic model explaining cure. Clin. Pharm. Therapeut. 87, 706–713,862
2010.863
25. X. Song and A.U. Neumann. Global stability and periodic solution of the viral dynamics. J. Math. Anal. Appl.864
329, 281–297, 2007.865
26. M. Tanaka, T. Itoh, N. Tanimizu and A. Miyajima. Liver stem/progenitor cells: their characteristics and866
regulatory mechanisms. J. Biochem. 149, 231–239, 2011.867
27. V. TenCate, B. Sainz Jr, S.J. Cotler and S.L. Uprichard. Potential treatment options and future research to868
increase hepatitis C virus treatment response rate. Hepat. Med. 2, 125–145, 2010.869
28. R. Turner, O. Lozoya, Y. Wang, V. Cardinale, E. Gaudio, G. Alpini, G. Mendel, E. Wauthier, C. Barbier, D.870
Alvaro and L.M. Reid. Human hepatic stem cell and maturational liver lineage biology. Hepatology 53,871
1035–1045, 2011.872
29. S. Wiggins. Introduction to Applied Nonlinear Dynamical Systems and Chaos, second edition, Texts in Applied873
Mathematics vol 2, Springer, New York, 2003.874
c© 2018 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
875
876
